WO2005056781A1 - Utilisation des proteines et des peptides codes par le genome d'une nouvelle souche de coronavirus associe au sras. - Google Patents
Utilisation des proteines et des peptides codes par le genome d'une nouvelle souche de coronavirus associe au sras. Download PDFInfo
- Publication number
- WO2005056781A1 WO2005056781A1 PCT/FR2004/003105 FR2004003105W WO2005056781A1 WO 2005056781 A1 WO2005056781 A1 WO 2005056781A1 FR 2004003105 W FR2004003105 W FR 2004003105W WO 2005056781 A1 WO2005056781 A1 WO 2005056781A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sars
- protein
- strain
- cov
- recombinant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
Definitions
- the present invention relates to a novel strain of coronavirus associated with severe acute respiratory syndrome (SARS), resulting from a specimen collected under the auspices of the present invention.
- SARS severe acute respiratory syndrome
- No. 031589 and taken from Hanoi (Vietnam) nucleic acid molecules derived from its genome, proteins and peptides encoded by said nucleic acid molecules and their applications, especially as diagnostic reagents and / or as a vaccine.
- the coronavirus is a single stranded, positive polarity, approximately 30 kilobase RNA virus that replicates in the cytoplasm of host cells; the 5 'end of the genome has a cap structure and the 3' end has a polyA tail.
- This virus is enveloped and includes, on its surface, peplomeric structures called spicules.
- the genome comprises the following open reading frames or ORFs, from its 5 'end to its 3' end: ORF 1a and ORF1b corresponding to the proteins of the transcription-replication complex, and ORF-S, ORF-E, ORF-M and ORF-N corresponding to the structural proteins S, E, M and N. It also comprises ORFs corresponding to proteins of unknown function encoded by: and overlapping the region between the ORF-S and the ORF-E, the region between the ORF-M and the ORF-N, and the region included in the ORF-N.
- Protein S is a membrane glycoprotein (200-220 kDa) that is in the form of spikes or "spike” emerging from the surface of the viral envelope. It is responsible for the attachment of the virus to the receptors of the host cell and the induction of viral envelope fusion with the cell membrane.
- the small envelope protein (E) also called sM (small membrane) which is an unglycosylated trans-membrane protein of about 10 kDa, is the protein present in a smaller amount in the virion.
- Protein M or matrix protein (25-30 kDa) is a more abundant membrane glycoprotein that is integrated into the viral particle by an ME interaction, whereas S incorporation into particles is driven by an S / S interaction. Mr. It appears to be important for the viral maturation of coronaviruses and for the determination of the site at which viral particles are assembled. Protein N, or nucleocapsid protein (45-50 kDa), which is the most conserved among the structural proteins of coronaviruses, is necessary to encapsidate genomic TARN and then to direct its incorporation into the virion.
- This protein is likely also involved in the replication of RNA.
- ORF reading frame
- the reading frame (ORF) located 5 'of the viral genome is translated into a polyprotein which is cleaved by viral proteases and then releases several nonstructural proteins such as RNA polymerase RNA dependent (Rep) and ATPase helicase (Hel). Both proteins are involved in the replication of the viral genome as well as in the generation of transcripts that are used in the synthesis of viral proteins.
- Rep RNA polymerase RNA dependent
- Hel ATPase helicase
- the proteins of the viral membrane are inserted into the intermediate compartment, whereas the replicated RNA (+ strand) assembles with the N protein (nucleocapsid).
- This protein-RNA complex then associates with the M protein included in the endoplasmic reticulum membranes and the viral particles are formed when the core nucleocapsid complex buds into the endoplasmic reticulum.
- the virus then migrates through the Golgi complex and eventually exits the cell, for example by exocytosis.
- the site of attachment of the virus to the host cell is at the level of the S protein. Coronaviruses are responsible for 15 to 30% of colds in humans and respiratory or digestive infections in animals, including cats.
- FIG. 1 Feline infectious peritonitis virus
- poultry IBV: Avian Infections bronchitis virus
- mouse MHV: Mouse Hepatitis virus
- pork TGEV: Transmissible gastroenteritis virus
- PEDV Porcine Epidemic Diarrhea virus
- PRCoV Porcine Respiratory Coronavirus
- HEV Hemagglutinating Encephalomyelitis Virus
- Cattle BcoV: Bovine Coronavirus.
- each coronavirus affects only one species; in immunocompetent individuals, the infection induces possibly neutralizing antibodies and cellular immunity, capable of destroying the infected cells.
- SARS Severe Acute Respiratory Syndrome
- Genome sequences of this new coronavirus have thus been obtained, in particular those of the isolate Urbani (Genbank accession number AY274119.3 and A. MARRA et al., Science, May 1, 2003, 300, 1399-1404) and of Toronto isolate (Tor2, Genbank Accession No. AY 278741 and A. ROTA et al., Science, 2003, 300, 1394-1399).
- the organization of the genome is comparable to that of other known coronviruses, thus confirming the SARS-CoV membership of the family Coronaviridae; the open ORF reading frames la and lb and the open reading frames corresponding to the S, E, M, and N proteins, as well as proteins encoded by: the region between the ORF-S and the ORF- E (ORF3), the region between ORF-S and ORF-E and overlapping ORF-E (ORF4), the region between ORF-M and ORF-N (ORF7 to ORF1) 1) and the region corresponding to the ORF-N (ORF13 and ORF14) have been identified.
- SARS-CoV is far from other coronaviruses and has been shown to be either by mutation of human respiratory coronaviruses or by recombination between known coronaviruses (for a review, see Holmes, JCI, 2003, 111, 1605-1609).
- the identification and consideration of new variants is important for the development of sufficiently sensitive and specific SARS detection and diagnostic reagents as well as for immunogenic compositions capable of protecting populations against SARS outbreaks.
- the inventors have now identified another strain of SARS-associated coronavirus, which is different from the Tor2 and Urbani isolates.
- the subject of the present invention is therefore an isolated or purified strain of human coronavirus associated with severe acute respiratory syndrome, characterized in that its genome has, in the form of complementary DNA, a serine codon at position 23220-23222 of the protein S or a glycine codon at position 25298-25300 of the 1ORF3 gene, and an alanine codon at position 7918-7920 of ORFla or a serine codon at position 26857-26859 of the M protein gene, said positions being indicated with reference to Genbank sequence AY274119.3.
- the DNA equivalent of its genome has a sequence corresponding to the sequence
- SEQ ID NO: 1 this strain of coronavirus is derived from the bronchoalveolar lavage sample of a patient with SARS, listed under the number 031589 and carried out at the French hospital in Hanoi (Vietnam).
- said sequence SEQ ID NO: 1 is that of the deoxyribonucleic acid corresponding to the ribonucleic acid molecule of the genome of the isolated strain of coronavirus as defined above.
- the sequence SEQ ID NO: 1 differs from the Genbank sequence AY274119.3 (isolate Tor2) in that it possesses the following mutations: g / t at position 23220; the alanine codon (gct) at position 577 of the amino acid sequence of the Tor2 protein S is replaced by a serine codon (tct), - a / g at position 25298; the arginine codon (aga) at position 11 of the amino acid sequence of the protein encoded by Tor 2 ORF3 is replaced by a glycine codon (gga).
- sequence SEQ ID NO: 1 differs from the Genbank sequence AY278741 (isolate Urbani) in that it possesses the following mutations: t / c at position 7919; the valine codon (gtt) at position 2552 of the amino acid sequence of the protein encoded by ORF la is replaced by an alanine codon (gct), - t / c at position 16622: this mutation does not modify the sequence in amino acids of the ORF1b encoded proteins (silent mutation), - g / a in position 19064: this mutation does not modify the amino acid sequence of the ORF1b encoded proteins (silent mutation), - c / t in position 24872: this mutation does not modify the amino acid sequence of the S protein, and - c / t at position 26857: the proline codon (ccc) at position 154 of the amino acid sequence of the M protein is replaced by a codon serine (tcc).
- the present invention also relates to an isolated or purified polynucleotide, characterized in that its sequence is that of the genome of the isolated strain of coronavirus as defined above. According to an advantageous embodiment of said polynucleotide, it has the sequence SEQ ID NO: 1.
- the present invention also relates to an isolated or purified polynucleotide, characterized in that its hybrid sequence under conditions of high stringency with the sequence of the polynucleotide as defined above.
- isolated or purified mean modified "by the hand of man” from the natural state; in other words, if an object exists in nature, it is said to be isolated or purified if it has been modified or extracted from its natural environment or both.
- a polynucleotide or protein / peptide naturally present in a living organism is neither isolated nor purified; on the other hand, the same polynucleotide or protein / peptide separated from the coexisting molecules in its natural environment, obtained by cloning, amplification and / or chemical synthesis, is isolated within the meaning of the present invention.
- a polynucleotide or a protein / peptide that is introduced into an organism by transformation, genetic manipulation or any other method is "isolated” even though it is present in the organism.
- the purified term as used in the present invention means that the proteins / peptides according to the invention are essentially free from association with other proteins or polypeptides, as is for example the purified product of the host cell culture. recombinant or the purified product from a non-recombinant source.
- high-stringency hybridization conditions are understood to mean temperature and ionic strength conditions chosen in such a way as to allow the maintenance of specific and selective hybridization between complementary polynucleotides.
- conditions of high stringency for the purpose of defining the above polynucleotides are advantageously as follows: DNA-DNA or DNA-RNA hybridization is carried out in two steps: (1) prehybridization at 42 ° C. for 3 hours in phosphate buffer (20 mM pH 7.5) containing 5 x SSC (1 x SSC corresponds to a solution 0.15 M NaCl + 0.015 M sodium citrate), 50% formamide, 7% sodium dodecyl sulfate (SDS), Denhardt's x 10, 5% dextran sulfate and 1% salmon sperm DNA; (2) hybridization for 20 hours at 42 ° C followed by 2 washes for 20 minutes at 20 ° C in 2 x SSC + 2% SDS, 1 wash for 20 minutes at 20 ° C in 0.1 x SSC + 0.1 % SDS.
- the present invention also relates to a fragment representing tative of the polynucleotide as defined above, characterized in that it is capable of being obtained, either by the use of restriction enzymes whose recognition and cleavage sites are present in said polynucleotide as defined herein above, or by amplification using oligonucleotide primers specific for said polynucleotide as defined above, either by in vitro transcription or by chemical synthesis.
- said fragment is selected from the group consisting of: the cDNA corresponding to at least one open reading frame (ORF) chosen from: ORF 1a, ORF1b, ORF-S, ORF-E, ORF -M, ORF-N, ORF3, ORF4, ORF7 to ORF1, ORF13 and ORF14, and the cDNA corresponding to the 5 'or 3' non-coding ends of said polynucleotide.
- ORF open reading frame
- said fragment has a sequence selected from the group consisting of: the sequences SEQ ID NO: 2 and 4 representing the cDNA corresponding to the ORF-S which encodes the protein S, the sequences SEQ ID NO: 13 and 15 representing the cDNA corresponding to the ORF-E which encodes the protein E, the sequences SEQ ID NO: 16 and 18 representing the cDNA corresponding to the ORF.
- the subject of the present invention is also a fragment of the cDNA coding for the protein S, as defined above, characterized in that it has a sequence selected from the group consisting of the sequences SEQ ID NO: 5 and 6 (fragments Sa and Sb).
- the subject of the present invention is also a fragment of the cDNA corresponding to the ORF 1a and ORF 1b as defined above, characterized in that it has a sequence selected from the group consisting of the sequences SEQ ID NO: 41 to 54 (fragments L0 to L12).
- the present invention also relates to a fragment of the polynucleotide as defined above, characterized in that it has at least 15 consecutive bases or base pairs of the genome sequence of said strain including at least one of those located in position 7979, 16622, 19064, 23220, 24872, 25298 and 26857.
- it is a fragment of 20 to 2500 bases or base pairs, preferably 20 to 400.
- it includes at least one pair of bases or base pairs corresponding to the following positions: 7919 and 23220, 7919 and 25298, 16622 and 23220, 19064 and 23220, 16622 and
- the subject of the present invention is also primers of at least 18 bases capable of amplifying a fragment of the genome of a coronavirus associated with the SARS or the DNA equivalent of it.
- primers they are selected from the group consisting of: - primer pair No. 1 corresponding respectively to positions 28507 to 28522 (sense primer, SEQ ID NO: 60) and 28774 to 28759 ( antisense primer, SEQ ID NO: 61) of the polynucleotide sequence as defined above, primer pair No. 2 corresponding to positions 28375 to 28390 (sense primer, SEQ ID NO: 62) and 28702 to 28687 (antisense primer,
- the present invention also relates to a probe capable of detecting the presence of the genome of a coronavirus associated with SARS or a fragment thereof, characterized in that it is selected from the group consisting of: the fragments as defined above and the fragments corresponding to the positions of the polynucleotide sequence as defined above: 28561 to 28586, 28588 to 28608, 28541 to 28563 and 28565 to 28589 (SEQ ID NO: 64 to 67).
- the probes and primers according to the invention may be labeled directly or indirectly by a radioactive or non-radioactive compound by methods well known to those skilled in the art, in order to obtain a detectable and / or quantifiable signal.
- a radioactive or non-radioactive compound by methods well known to those skilled in the art, in order to obtain a detectable and / or quantifiable signal.
- the non-radioactive entities are selected from ligands such as biotin, avidin, streptavidin , digoxygenine, haptens, dyes, luminescent agents such as radioluminescent, chemiluminescent, bioluminescent, fluorescent, phosphorescent agents.
- the invention encompasses probes and labeled primers derived from the foregoing sequences.
- the present invention also relates to a method for detecting a SARS-associated coronavirus from a biological sample, which method is characterized in that it comprises at least: (a) nucleic acid extraction present in said biological sample, (b) amplification of a fragment of ORF-N by RT-PCR using a pair of primers as defined above, and (c) detection by any appropriate means of the amplification products obtained in (b).
- the amplification products (amplicons) in (b) are 268 bp for primer pair # 1 and 328 bp for primer pair # 2.
- the detection step (b) is carried out using at least one probe corresponding to positions 28561 to 28586, 28588 to 28608, 28541 to 28563 and 28565 to 28589 of the sequence of the polynucleotide as defined above.
- the SARS-associated coronavirus genome is detected and possibly quantified by real-time PCR, using the pair of primers No. 2 and probes corresponding to positions 28541 to 28563 and 28565 to 28589 labeled with different compounds, especially different fluorescers.
- the invention encompasses polydeoxyribonucleotides and single-stranded, double-stranded and tripe-stranded polybranch nucleotides corresponding to the genome sequence of the strain isolated from coronavirus and its fragments as defined above, as well as to their complementary sequences, sense or antisense, in particular RNAs and cDNAs corresponding to the sequence of the genome and its fragments as defined above.
- the present invention also encompasses the amplification fragments obtained using primers specific to the genome of the purified or isolated strain as defined above, in particular using primers and primer pairs.
- the restriction fragments constituted by or comprising the sequence of the fragments as defined above, the fragments obtained by in vitro transcription from a vector containing the sequence SEQ ID NO: 1 or a fragment as defined above, as well as fragments obtained by chemical synthesis.
- restriction fragments are deduced from the restriction map of the sequence SEQ ID NO: 1 illustrated in FIG. 13. In accordance with the invention, said fragments are either in the form of isolated fragments or in the form of mixtures of fragments. .
- the invention also encompasses modified fragments, relative to the above, by removal, or addition of nucleotides in a proportion of about 15%, relative to the length of the fragments above and / or modified at the nature of the nucleotides, since the modified nucleotide fragments retain a hybridization capacity with the genomic or antigenome RNA sequences of the isolate as defined above.
- the nucleic acid molecules according to the invention are obtained by conventional methods, known in themselves, following the standard protocols such as those described in Current Protocols in Molecular Biology (Frederick M. AUSUBEL, 2000, Wiley and Son Inc. Library of Congress, USA). For example, they can be obtained by amplification of a nucleic sequence by PCR or RT-PCR or by total or partial chemical synthesis.
- the present invention also relates to a chip or DNA or RNA filter, characterized in that it comprises at least one polynucleotide or one of its fragments as defined above.
- the chips or DNA or RNA filters according to the invention are prepared by conventional methods, known per se, such as, for example, chemical or electrochemical grafting of oligonucleotides on a glass or nylon support.
- the subject of the present invention is also a vector for cloning and / or recombinant expression, in particular a plasmid, a virus, a viral vector or a folding comprising a nucleic acid fragment as defined above.
- said recombinant vector is an expression vector wherein said nucleic acid fragment is under the control of appropriate transcriptional and translational regulatory elements.
- said vector may comprise sequences (labels or tag) fused in phase with the 5 'and / or 3' end of said insert, useful for the immobilization, and / or the detection and / or purification of the protein expressed from said vector.
- nucleic acid molecule of interest in order to introduce and maintain it in a host cell
- choice of an appropriate vector depends on the use envisaged for this vector (for example replication of the sequence of interest, expression of this sequence, maintenance of the sequence in extrachromosomal form or integration into the chromosomal material of the host), as well as the nature of the host cell.
- said plasmid is in particular selected from the following plasmids: the plasmid, called SARS-S, included in the bacterial strain deposited under No.
- this plasmid comprises an insert of sequence SEQ ID NO: 38 and is included in a bacterial strain which has been deposited under No. 1-3048, on June 5, 2003, with the National Collection of Cultures of Microorganisms. , 25 rue du Dondel Roux, 75724 Paris Cedex 15, - the plasmid called SARS-5'NC, included in the bacterial strain deposited under No. I-3124, on November 7, 2003, from the Collection
- the expression plasmid called pIV2.4N containing a cDNA fragment coding for an N-terminal fusion of protein N (SEQ ID NO: 3) with a polyhistidine label
- the expression plasmid called pIV2.4Sc or pIV2.4S 15 containing an insert coding for an N-terminal fusion of the fragment corresponding to positions 475 to 1193 of the amino acid sequence of the protein S (SEQ ID NO: 3) with a polyhistidine label
- the expression plasmid called PIV2.4SL containing a cDNA fragment coding for an N-terminal fusion of the fragment corresponding to the positions 14 to 1193 of the amino acid sequence of protein S (SEQ ID NO: 3) with a polyhistidine tag.
- the expression plasmid as defined above it is included in a bacterial strain which was deposited under No. I-3117, on October 23, 2003, with the National Collection of Cultures of Microorganisms, 25 rue du Dondel Roux, 75724 Paris Cedex 15. According to another advantageous arrangement of the expression plasmid as defined above, it is included in a bacterial strain which has been deposited under No. I-3118, on October 23 2003, from the National Collection of Cultures of Microorganisms, 25 rue du Do Budapest Roux, 75724 Paris Cedex 15.
- the present invention also relates to a nucleic acid insert of viral origin, characterized in that it is contained in any one of the strains as defined above in a) -r).
- the subject of the present invention is also a nucleic acid comprising a synthetic gene allowing optimized expression of the S protein in eukaryotic cells, characterized in that it possesses the sequence SEQ ID NO: 140.
- the subject of the present invention is also a expression vector comprising a nucleic acid comprising a synthetic gene as permet- optimized expression of the S protein, which vector is contained in the bacterial strain deposited at the CNCM on 1 December 2004, under No. I-3333.
- said expression vector it is a viral vector, in the form of a viral particle or in the form of a recombinant genome.
- this embodiment is a recombinant viral particle or a recombinant viral genome that can be obtained by transfection of a plasmid according to subparagraphs g), h) and k) to r) as defined above, in a suitable cellular system, i.e., for example, cells transfected with one or more other plasmid (s), intended to complete some of the functions of the virus deleted in the vector and necessary for the formation of viral particles.
- S-protein family is understood to mean the complete S protein, its ectodomain and fragments of this ectodomain which are preferably produced in a eukaryotic system.
- the present invention also relates to a viral lenti vector encoding a polypeptide of the S protein family, as defined above.
- the present invention also relates to a recombinant measles virus encoding a polypeptide of the S protein family, as defined above.
- the present invention also relates to a recombinant vaccinia virus encoding a polypeptide of the S protein family, as defined above.
- the subject of the present invention is also the use of a vector according to subparagraphs e) to r) as defined above, or of a vector comprising a synthetic protein S gene, as defined above, for the eukaryotic production of protein S of SARS-associated coronavirus, or a fragment thereof.
- the subject of the present invention is also a method for producing the protein S in the eukaryotic system, comprising a step of transfection of eukaryotic cells in culture by a vector chosen from the vectors contained in the bacterial strains mentioned in subparagraphs e) to r ) or a vector comprising a synthetic gene allowing optimized expression of the S protein.
- the subject of the present invention is also a cDNA library characterized in that it comprises fragments as defined above, in particular amplification fragments or restriction fragments, cloned into a recombinant vector, in particular an expression vector (expression library).
- the subject of the present invention is also cells, in particular prokaryotic cells, modified with a recombinant vector as defined above.
- the present invention also relates to a genetically modified eukaryotic cell expressing a protein or a polypeptide as defined below.
- the term "genetically modified eukaryotic cell” does not refer to a cell modified with a wild-type virus.
- it is capable of being obtained by transfection by any of the vectors mentioned in paragraphs (k) to (n) above.
- it is the FRhK4-Ssol-30 cell, deposited at the CNCM on November 22, 2004, under No. I-3325.
- the recombinant vectors as defined above and the cells transformed with said expression vectors are advantageously used for the production of the corresponding proteins and peptides.
- the expression libraries derived from said vectors, as well as the cells transformed by said banks expression are advantageously used to identify the immunogenic epitopes (B and T epitopes) of SARS-associated coronavirus proteins.
- the present invention also relates to purified or isolated proteins and peptides, characterized in that they are encoded by the polynucleotide or one of its fragments as defined above.
- said protein is selected from the group consisting of: protein S of sequence SEQ ID NO: 3 or its ectodomain - protein E of sequence SEQ ID NO: 14 - protein M of sequence SEQ ID NO: 17 - the N protein of sequence SEQ ID NO: 37 - the proteins encoded by the ORFs: ORFla, ORF1b, ORF3, ORF4 and ORF7 to ORF1, ORF13 and ORF14 respectively, SEQ ID NO: 74, 75, 10, 12, 22, 24, 26, 28, 30, 33 and 35.
- the terms "ectodomain of the protein S” and "soluble form of the protein S" will be used interchangeably.
- said polypeptide consists of the amino acids corresponding to the positions 1 to 1193 of the amino acid sequence of the protein S
- said peptide is selected in the group consisting of: a) peptides corresponding to positions 14 to 1193 and 475 to 1193 of the amino acid sequence of protein S, b) peptides corresponding to positions 2 to 14 (SEQ ID NO: 69) and 100 at 221 of the amino acid sequence of the M protein; these peptides correspond respectively to the ectodomain and endodomain of the M protein, and c) the peptides corresponding to positions 1 to 12 (SEQ ID NO: 70) and 53 to 76 (SEQ ID NO: 71) of the sequence amino acids of the protein E; these peptides correspond respectively to the ectodomain and the C-terminal end of the protein E, and d) peptides from 5 to 50 consecutive amino acids, preferably from 10 to 30 amino acids, included or overlapping partially or
- the subject of the present invention is also a peptide characterized in that it has a sequence of 7 to 50 amino acids, including an amino acid residue selected from the group consisting of: alanine located at position 2552 of the sequence in amino acids of the protein encoded by ORF la. the serine located at position 577 of the amino acid sequence of the S protein of the strain of SARS-CoV as defined above, the glycine at position 11 of the amino acid sequence of the protein encoded by 1ORF3 of the strain of SARS-CoV as defined above, the serine at position 154 of the amino acid sequence of the M protein of the SARS-CoV strain as defined above.
- the present invention also relates to an antibody or a polyclonal or monoclonal antibody fragment, obtainable by immunization of an animal with a recombinant vector as defined above, a cDNA library as defined herein. above or a protein or a peptide as defined above, characterized in that it binds with at least one of the proteins encoded by the SARS-CoV as defined above.
- the invention encompasses polyclonal antibodies, monoclonal antibodies, chimeric antibodies such as humanized antibodies, and fragments thereof (Fab, Fv, scFv).
- the subject of the present invention is also a hybridoma producing a monoclonal antibody against the N protein, characterized in that it is chosen from the following hybridomas: the hybridoma producing the monoclonal antibody 87, deposited at the CNCM on 1 December 2004 under number 1-3328, - hybridoma producing the monoclonal antibody 86, deposited at the CNCM on December 1, 2004 under number 1-3329, - hybridoma producing the monoclonal antibody 57, tabled in CNCM on December 1, 2004 under number 1-3330, and - hybridoma producing the monoclonal antibody 156, deposited at CNCM on December 1, 2004 under number 1-3331.
- the subject of the present invention is also an antibody or polyclonal or monoclonal antibody fragment directed against the N protein, characterized in that it is produced by a hybridoma as defined above.
- the term "chimeric antibody” means, relative to an antibody of a particular animal species or of a particular class of antibody, an antibody comprising all or part of a heavy chain and / or a a light chain of an antibody of another animal species or another class of antibodies.
- humanized antibody is intended to mean a human immunoglobulin in which the residues of the CDRs (Complementary-Determining Regions) which form the antigen-binding site are replaced by those of a non-human monoclonal antibody possessing the specificity, affinity or activity sought.
- CDRs Complementary-Determining Regions
- humanized antibodies are less immunogenic and have a prolonged half-life in humans because they possess only a small proportion of non-human sequences, since almost all FR regions (Framework) and the constant region (Fc) of these antibodies are those of a consensus sequence of human immunoglobulins.
- the present invention also relates to a chip or protein filter, characterized in that it comprises a protein, a peptide or an antibody as defined above.
- the protein chips according to the invention are prepared by conventional methods, known in themselves. Suitable carriers on which proteins may be immobilized include those made of plastic or glass, especially in the form of microplates.
- the present invention also relates to reagents derived from the strain isolated from SARS-associated coronavirus, from the sample numbered 031589, useful for the study and diagnosis of infection caused by a coronavirus associated with SARS, which reagents are selected from the group consisting of: (a) a primer pair, a probe or a DNA chip as defined above, (b) a recombinant vector or a modified cell as defined above, (c) an isolated strain of coronavirus or a polynucleotide as defined above, (d) a protein or a peptide as defined above, (e) an antibody or antibody fragment as defined above, and (f) a protein chip such as defined above.
- nucleic acid fragments according to the invention are prepared and used according to the conventional techniques as defined above.
- the peptides and proteins according to the invention are prepared by recombinant DNA techniques known to those skilled in the art, in particular using the recombinant vectors as defined above.
- the peptides according to the invention can be prepared by conventional solid or liquid phase synthesis techniques known to those skilled in the art.
- the polyclonal antibodies are prepared by immunizing an appropriate animal with a protein or a peptide as defined above, optionally coupled to KLH or albumin and / or combined with a suitable adjuvant such as Freund's adjuvant.
- the antibodies are harvested by taking the serum of the immunized animals and enriched with IgG by precipitation, according to standard techniques, then the SARS-CoV protein-specific IgGs are optionally purified by chromatography of affinity on an appropriate column on which are fixed said peptide or said protein, as defined above, so as to obtain a monospecific IgG preparation.
- the monoclonal antibodies are produced from hybridomas obtained by fusion of B lymphocytes of an animal immunized with a protein or a peptide as defined above with myelomas, according to the technique of Kohler and Milstein (Nature, 1975, 256 495-497); the hybridomas are cultured in vitro, in particular in fermentors or produced in vivo, in the form of ascites; alternatively said monoclonal antibodies are produced by genetic engineering as described in US Patent 4,816,567. Humanized antibodies are produced by general methods such as those described in International Application WO 98/45332.
- Antibody fragments are produced from cloned V H and V regions from hybridoma or splenic lymphocyte mRNAs of an immunized mouse; for example, Fv, scFv or Fab fragments are expressed on the surface of filamentous phages according to the technique of Winter and Milstein (Nature, 1991, 349, 293-299); after several selection steps, the antigen-specific antibody fragments are isolated and expressed in an appropriate expression system, by standard techniques of cloning and expression of recombinant DNA.
- the antibodies or their fragments as defined above are purified by standard techniques known to those skilled in the art, such as affinity chromatography.
- the present invention further relates to the use of a product selected from the group consisting of: a pair of primers, a probe, a DNA chip, a recombinant vector, a modified cell, an isolated strain of coronavirus, a polynucleotide, a protein or a peptide, an antibody or an antibody fragment and a protein chip as defined above, for the preparation of a detection reagent and, optionally, genotyping / serotyping, of an associated coronavirus SARS.
- a product selected from the group consisting of: a pair of primers, a probe, a DNA chip, a recombinant vector, a modified cell, an isolated strain of coronavirus, a polynucleotide, a protein or a peptide, an antibody or an antibody fragment and a protein chip as defined above, for the preparation of a detection reagent and, optionally, genotyping / serotyping, of an associated coronavirus SARS.
- proteins and peptides according to the invention which are capable of being recognized and / or of inducing the production of antibodies specific for SARS-associated coronavirus, are useful for the diagnosis of infection by such a coronavirus; the infection is detected by a suitable technique - in particular EIA, ELISA, RJA, immunofluorescence-, from a biological sample taken from an individual who may be infected.
- said proteins are selected from the group consisting of the S, E, M and / or N proteins and the peptides as defined above.
- the S, E, M and / or N proteins and the peptides derived from these proteins as defined above, for example the N protein are used for the indirect diagnosis of a coronavirus infection associated with SARS (serological diagnosis; detection of SARS-CoV specific antibodies), in particular by an immunoenzymatic method (ELISA).
- the antibodies and the antibody fragments according to the invention in particular those directed against the proteins S, E, M and / or N and the peptides derived as defined above, are useful for the direct diagnosis of a human infection.
- coronavirus associated with SARS; the detection of SARS-CoV protein (s) is carried out by an appropriate technique, in particular EIA, ELISA, RIA, immunofluorescence from a biological sample taken from an individual susceptible to infection.
- the present invention also relates to a method for detecting a coronavirus associated with SARS, from a biological sample, which method is characterized in that it comprises at least: (a) contacting said biological sample with at least one antibody or an antibody fragment, a protein, a peptide or a protein or peptide chip or filter as defined above, and (b) revealing by any appropriate means the antigen-antigen complexes.
- antibodies formed in (a) for example by EIA, ELISA, RIA, or immunofluorescence.
- step (a) comprises: (a) bringing said biological sample into contact with at least a first antibody or an antibody fragment which is fixed on a suitable support, in particular a microplate; (a 2 ) the washing of the solid phase, and (a 3 ) the addition of at least a second antibody or an antibody fragment, different from the first, said antibody or antibody fragment being optionally labeled appropriately.
- a suitable support in particular a microplate
- step (a) comprises: (a) bringing said biological sample into contact with at least a first antibody or an antibody fragment which is fixed on a suitable support, in particular a microplate; (a 2 ) the washing of the solid phase, and (a 3 ) the addition of at least a second antibody or an antibody fragment, different from the first, said antibody or antibody fragment being optionally labeled appropriately.
- This method which makes it possible to capture the viral particles present in the biological sample is also called the immunocapture method.
- step (a1) is carried out with at least a first monoclonal or polyclonal antibody or a fragment thereof, directed against the protein S, M, and / or E, and / or a peptide corresponding to the ectodomain of one of these proteins (peptides M2-14 or El-12)
- step (a 3 ) is carried out with at least one antibody or an antibody fragment directed against another epitope of the same protein or preferably against another protein, preferably against an internal protein such as nucleoprote N or Pendodomaine protein E or M, even more preferably it is antibodies or fragments of antibodies against the N protein which is very abundant in the viral particle; when an antibody or an antibody fragment directed against an internal protein (N) or against Pendodomaine E or M proteins is used, said antibody is incubated in the presence of detergent, such as Tween 20 for example, at concentrations of the order of 0.1%.
- detergent such as Tween 20 for example
- step (b) of revealing the antigen-antibody complexes formed is carried out, either directly with the aid of a second antibody labeled for example with biotin or an appropriate enzyme such as peroxidase or alkaline phosphatase, or indirectly using an anti-immunoglobulin serum labeled as above.
- the complexes thus formed are revealed using a suitable substrate.
- the biological sample is mixed with the monoclonal antibody of revelation prior to its contact with the monoclonal capture antibodies. If desired, the serum-revealing antibody mixture is incubated for at least 10 minutes at room temperature before being applied to the plate.
- the present invention also relates to an immunocapture assay for detecting SARS-associated coronavirus infection by detection of the native nucleoprotein (N protein), in particular characterized in that the antibody used for the capture of the native viral nucleoprotein is a monoclonal antibody specific for the central region and / or a conformational epitope.
- the antibody used for capture of the N protein is the monoclonal antibody mAb87 produced by the hybridoma deposited at the CNCM on December 1, 2004 under number 1-3328.
- the antibody used for capture of the N protein is the monoclonal antibody mAb86 produced by the hybridoma deposited at the CNCM on December 1, 2004 under number I-3329
- the monoclonal antibodies Acm86 and Acm87 are used for the capture of the N protein.
- a combination of the Acm57 and Acm87 antibodies, conjugated to a molecule or a revealing particle is used for the revelation of the N protein.
- a revealing molecule may be a radioactive atom, a dye or a fluorescent molecule.
- a developing particle may be, for example: colloidal gold, a magnetic particle or a latex ball.
- the present invention also relates to a reagent for detecting a coronavirus associated with SARS, characterized in that it is selected from the group consisting of: (a) a pair of primers or a probe as defined above (b) a recombinant vector as defined above or a modified cell as defined above, (c) an isolated strain of coronavirus as defined above or a polynucleotide as defined above, (d) ) a antibody or an antibody fragment as defined above, (e) a combination of antibodies comprising monoclonal antibodies Acm86 and / or Acm87, and monoclonal antibody Acm57, as defined above, (f) a chip or a filter as defined above.
- the present invention also relates to a method for detecting SARS-associated coronavirus infection from a biological sample by indirect IgG ELISA using protein N, which method is characterized in that the plaques are sensitized. by a solution of protein N at a concentration of between 0.5 and 4 ⁇ g / ml, preferably 2 ⁇ g / ml, in a PBS 1 OmM pH 7.2 buffer, phenol red at 0.25 ml IL.
- the present invention further relates to a method for detecting an infection with a SARS-associated coronavirus from a biological sample by double-epitope ELISA, characterized in that the test serum is mixed with the revealing antigen, said mixture then being brought into contact with the antigen fixed on a solid support.
- these tests combine an ELSA using the N protein and another ELSA using the S protein, as described below.
- the subject of the present invention is also an immune complex formed of an antibody or of a polyclonal or monoclonal antibody fragment as defined above, and of a protein or peptide of the coronavirus associated with SARS.
- the present invention further relates to a kit for detecting a coronavirus associated with SARS, characterized in that it comprises at least one reagent selected from the group consisting of: a pair of primers, a probe, a chip to DNA or RNA, a recombinant vector, a modified cell, an isolated strain of coronavirus, a polynucleotide, a protein or a peptide, an antibody, and a protein chip as defined above.
- the present invention further relates to an immunogenic composition, characterized in that it comprises at least one product selected from the group consisting of: a) a protein or a peptide as defined above, b) a polynucleotide of DNA or RNA type or one of its representative fragments as defined above, of sequence chosen from: (i) the sequence SEQ ID NO: 1 or its RNA equivalent (ii) the hybridizing sequence in conditions of high stringency with the sequence SEQ ID NO: 1, (iii) the sequence complementary to the sequence SEQ ID NO: 1 or of the hybridizing sequence under conditions of high stringency with the sequence SEQ ID NO: 1, (iv ) the nucleotide sequence of a representative fragment of the polynucleotide as defined in (i), (ii) or (iii), (v) the sequence as defined in (i), (ii), (iii) or (iv), modified, and c) a recombinant expression vector comprising a polynucleotide as defined in
- compositions according to the invention are good vaccine candidates and can be used in immunogenic compositions for the production of a vaccine against SARS-associated coronavirus.
- compositions according to the invention also contain at least one pharmaceutically acceptable vehicle and optionally carrier substances and / or adjuvants.
- the pharmaceutically acceptable vehicles, the carrier substances and the adjuvants are those conventionally used.
- the adjuvants are advantageously chosen from the group consisting of oily emulsions, saponin, mineral substances, bacterial extracts, alumina hydroxide and squalene.
- the carrier substances are advantageously selected from the group consisting of unilamellar liposomes, multilamellar liposomes, saponin micelles or solid microspheres of saccharide or auriferous nature.
- the compositions according to the invention are administered by the general route, in particular intramuscularly or subcutaneously, or by the local route, in particular the nasal route (aerosol).
- the present invention also relates to the use of an isolated or purified protein or peptide having a sequence selected from the group consisting of the sequences SEQ ID NO: 3, 10, 12, 14, 17, 22, 24 , 26, 28, 30,
- the subject of the present invention is also an immune complex formed of an isolated or purified protein or peptide having a sequence selected from the group consisting of the sequences SEQ ID NO: 3, 10, 12, 14, 17, 22
- the present invention also relates to the use of an isolated or purified protein or peptide having a sequence selected from the group consisting of the sequences SEQ ID NO: 3, 10, 12, 14, 17, 22, 24 , 26, 28, 30,
- the present invention also relates to the use of an isolated or purified polynucleotide having a sequence selected from the group consisting of the sequences SEQ ID NO: 1, 2, 4, 7, 8, 13, 15, 16, 18, 19, 20, 31, 36 and 38 for inducing the production of an antibody directed against the protein encoded by said polynucleotide and capable of specifically recognizing a SARS-associated coronavirus epitope.
- the subject of the present invention is also monoclonal antibodies which recognize the native protein S of a coronavirus associated with SARS.
- the subject of the present invention is also the use of a protein or a polypeptide of the S protein family, as defined above, or an antibody recognizing the native S protein, as defined above, for detecting SARS-associated coronavirus infection from a biological sample.
- the present invention also relates to a method for detecting infection with a SARS-associated coronavirus from a biological sample, characterized in that the detection is carried out by ELISA using the recombinant protein S, expressed in a eukaryotic system.
- it is a double epitope ELISA method, and the serum to be tested is mixed with the revealing antigen, said mixture then being brought into contact with the antigen. fixed on a solid support.
- the present invention also relates to an immune complex formed of an antibody or a monoclonal antibody fragment recognizing the native S protein, and a SARS-associated coronavirus protein or peptide.
- the subject of the present invention is also an immune complex formed of a protein or a polypeptide of the S protein family, as defined above, and of an antibody directed specifically against a SARS-associated coronavirus epitope. .
- the present invention further relates to a kit or kit for detecting a coronavirus associated with SARS, characterized in that it comprises at least one reagent selected from the group consisting of: a protein or a polypeptide of the family of the protein S, as defined above, a nucleic acid encoding a protein or polypeptide of the S protein family, as defined above, a cell expressing a protein or polypeptide of the S protein family, such as defined above, or an antibody recognizing the native S protein of a SARS-associated coronavirus.
- a kit or kit for detecting a coronavirus associated with SARS characterized in that it comprises at least one reagent selected from the group consisting of: a protein or a polypeptide of the family of the protein S, as defined above, a nucleic acid encoding a protein or polypeptide of the S protein family, as defined above, a cell expressing a protein or polypeptide of the S protein family, such as defined above, or an antibody recognizing the native
- the subject of the present invention is an immunogenic and / or vaccine composition, characterized in that it comprises a polypeptide or a recombinant protein of the S protein family, as defined above, obtained in a eukaryotic expression system. .
- the present invention also relates to an immunogenic and / or vaccine composition, characterized in that it comprises a vector or virus recombinant, expressing a protein or a polypeptide of the S protein family, as defined above.
- the invention also comprises other arrangements, which will emerge from the description which follows, which refers to examples of implementation of the polynucleotide representing the genome of the strain of SARS-CoV from the sample. listed under the number 031589, and derived cDNA fragments object of the present invention, as well as in Table I presenting the list of sequences:
- FIG. 1 illustrates the Western blot analysis of the in vitro expression of recombinant proteins N, Se and S L from the pIVEX expression vectors.
- Lane 1 pIV2.3N.
- Track 2 pIV2.3S c .
- Lane 3 pIV2.3S L.
- Lane 4 pIV2.4N.
- Lane 5 pIV2.4Sj or pIV2.4S c .
- Track 6 pIV2.4S L. Expression of the GFP protein expressed from the same vector is used as a control.
- FIG. 1 illustrates the Western blot analysis of the in vitro expression of recombinant proteins N, Se and S L from the pIVEX expression vectors.
- Lane 1 pIV2.3N.
- Track 2 pIV2.3S c .
- Lane 4 pIV2.4N.
- Lane 5 pIV2.4Sj or pIV2.4S c .
- Track 6 pIV2.4S L. Expression of the GFP protein expressed from the same vector is used as
- FIG. 2 illustrates the analysis by denaturing polyacrylamide gel electrophoresis (SDS-PAGE) and staining with Coomassie blue, of the in vivo expression of the N protein from the pIVEX expression vectors.
- the Eco // BL21 (D3) pDIA17 strain transformed with the recombinant pIV ⁇ X vectors is cultured at 30 ° C. in LB medium, in the presence or absence of an inducer (IPTG ImM).
- Track 2 pIV2.4N.
- FIG. 3 illustrates the analysis by denaturing polyacrylamide gel electrophoresis (SDS-PAG ⁇ ) and staining with Coomassie blue, of the in vivo expression of the S L and Se polypeptides from the vectors.
- pIVEX expression The strain BL21 (DE3) pDIA17 transformed by the recombinant pIVEX vectors is cultured at 30 ° C in LB medium, in the presence or absence of inducer (IPTG ImM). Track 1: ⁇ IV2.3S c Track 2: pIV2.3S L. Track 3: pIV2.4S ⁇ Track 4: pIV2.4S L.
- FIG. 4 illustrates the antigenic activity of the recombinant N, S L and Se proteins produced in the E.
- Lane 6 pIV2.4S L - Figure 5 illustrates the purification on a Ni-NTA agarose column of the recombinant N protein produced in E. coli strain BL21 (DE3) pDIA17 from the pIV2.3N vector. Lane 1: Total bacterial extract. Lane 2: Soluble extract. Lane 3: Insoluble extract. Lane 4: Extract deposited on the Ni-NTA column. Lane 5: Non-retained proteins. Lane 6: Fractions of peak 1. Lane 7: Fractions of peak 2. - Figure 6 illustrates the purification of recombinant protein Se from the inclusion bodies produced in E. coli strain BL21 (DE3) pDIA17 transformed by the pIV2.4S ⁇ .A.
- FIG. 7 represents the immunoblotting carried out using a lysate of cells infected with SARS-CoV and a serum of a patient suffering from atypical pneumonitis.
- FIG. 8 represents immunoblots made using a lysate of cells infected with SARS-CoV and antisera of rabbits specific for nucleoprotein N (A) and spike protein S (B).
- IS immune serum.
- pi pre-immune serum.
- Anti-N antiserum was used at 1/50000 and antiserum anti-S at 1/10000.
- FIG. 9 illustrates the ELISA reactivity of monospecific rabbit polyclonal sera directed against the N protein or the short S (Se) protein fragment, with respect to the corresponding recombinant proteins used for immunization.
- A rabbits P13097, P13081, and P13031 immunized with purified recombinant N protein.
- FIG. 10 illustrates the ELISA reactivity of the purified recombinant N protein with respect to serum of patients suffering from atypical pneumonia caused by SARS-CoV.
- FIG. 10a ELISA plates prepared with N protein at a concentration of 4 ⁇ g / ml and 2 ⁇ g / ml.
- 10b ELISA plate prepared with N protein at a concentration of 1 ⁇ g / ml. Serums designated A, B, D, E, F, G, H correspond to those of Table IV.
- FIG. 10a ELISA plates prepared with N protein at a concentration of 4 ⁇ g / ml and 2 ⁇ g / ml.
- 10b ELISA plate prepared with N protein at a concentration of 1 ⁇ g / ml.
- Serums designated A, B, D, E, F, G, H correspond to those of Table IV.
- FIG. 11 illustrates the amplification by RT-PCR of decreasing amounts of synthetic SARS-CoV N gene (10 7 to 1 copy), using primer pairs No. 1 (N / + / 28507, N / - / 28774) (A) and No. 2 (N / + / 28375, N / - / 28702) (B).
- T amplification carried out in the absence of RNA.
- MW DNA marker.
- FIG. 12 illustrates the real-time RT-PCR amplification of synthetic SARS-CoV N gene RNA: decreasing amounts of synthetic RNA in replicate (folds, lanes 16 to 29) as well as Viral RNA diluted 1 / 20x10 "4 (lane 32) were amplified by RT-PCR in real time using the" Light Cycler RNA Amplification Kit Hybridization Probes "kit and couples of primers and probes of the series No. 2, under the conditions described in Example 8.
- FIG. 13 (FIG. 13.1 to 13.70) represents the restriction map of the sequence SEQ ID NO: 1 corresponding to the DNA equivalent of the genome of the strain of SARS. -CoV from the sample numbered 031589.
- FIG. 14 shows the result of the SARS serology test by indirect ELISA N (first series of sera tested)
- Figure 15 shows the result of the SARS serology test by indirect ELISA N (2nd series of sera tested)
- FIG. 16 shows the result of the serotype ELISA N double epitope (first series of sera tested) serology test.
- FIG. 17 shows the result of the double epitope ELISA N (double serum test) serology test.
- FIG. 18 illustrates the test of reactivity of the anti-N monoclonal antibodies by ELISA on the native nucleoprotein N of SARS-CoV.
- Antibodies were assayed as hybridoma culture supernatants by indirect ELISA using an irradiated lysate of VeroE6 cells infected with SARS-CoV as an antigen (SARAS lysate curves). A negative reactivity control is performed for each antibody on a lysate of uninfected VeroE6 cells (negative lysate curves).
- SARAS lysate curves A negative reactivity control is performed for each antibody on a lysate of uninfected VeroE6 cells (negative lysate curves).
- Several monoclonal antibodies of known specificity have been used as negative control antibodies: parai -3 directed against antigens of type 1-3 parainfluenza virus (Bio-Rad) and influenza B directed against antigens of influenza type B virus ( Bio-Rad).
- FIG. 19 illustrates the reactivity test of the anti-N monoclonal antibodies of SARS-CoV by ELISA on the native antigens of the human coronavirus 229E (HCoV-229E).
- Antibodies were assayed as hybridoma culture supernatants by indirect ELISA using a lysate of MRC-5 cells infected with human coronavirus 229E as antigen (lysate 229E curves).
- a negative immunoreactivity control is performed for each antibody on a lysate of uninfected MRC-5 cells (negative lysate curves).
- Monoclonal antibody 5-11H.6 directed against the 229E human coronavirus S protein (Sizun et al., 1998, J.
- Virol Met 72: 145-152 is used as a positive control antibody.
- Para-3 antibodies to antigens of type 1-3 parainfluenza virus (Bio-Rad) and influenza B against influenza B virus antigens (Bio-Rad) were added to the monoclonal antibody panel tested.
- FIG. 20 shows a reagent test of the anti-N monoclonal antibodies of SARS-CoV by western blotting on the native nucleoprotein N of the denatured SARS-CoV.
- a lysate of VeroE6 cells infected with SARS-CoV was prepared in the Laemmli deposition buffer and migrated in a 12% SDS polyacrylamide gel and the proteins were transferred to a PVDF membrane.
- the anti-N monoclonal antibodies tested were used for the concentration immunoassay. 0.05 ⁇ g / ml. The revelation is made with peroxidase-coupled anti-mouse IgG (H + L) antibodies (NA93IV, Amersham) and the ECL + system. Two monoclonal antibodies were used as negative controls for reactivity: influenza B directed against antigens of the influenza virus type B (Bio-Rad) and parai -3 directed against the antigens of parainfluenza virus type 1-3 (Bio- Rad).
- Figure 21 shows the mammalian cell expression plasmids of the S protein of SARS-CoV.
- the S-cDNA of SARS-CoV was inserted between the BamHI and XhoI sites of the expression plasmid ⁇ cDNA3.1 (+) (Clontech) to obtain the plasmid pcDNA-S and between the NheI and XhoI sites of the plasmid.
- pCI expression Promega
- the WPRE and CTE sequences were inserted into each of the two pcDNA-S and pCI-S plasmids between the XhoI and XbaI sites to obtain respectively the pcDNA-S-CTE, pcDNA-S-WPRE, pCI-S-CTE and pCI plasmids.
- SP predicted signal peptide (aa 1-13) with signalP v2.0 software (Nielsen et al., 1997, Protein Engineering, 10: 1-6)
- TM predicted transmembrane region (aa 1196-1218) with TMHMM software v2.0 (Sonnhammer et al., 1998, Proceedings of Sixth Int.
- amino acids W1194 and P1195 are possibly part of the transmembrane region with probabilities of 0.13 and 0.42 P-CMV respectively: immediate / early cytomegalovirus promoter.
- BGH pA bovine growth hormone polyadenylation signal
- SV40 late pA late polyadenylation signal of SV40 virus SD / SA: donor and splice acceptor sites
- WPRE Woodchuck Hepatitis Virus sequences posttranscriptio- nal regulatory element of the marmot hepatitis virus
- CTE sequences of the "constitutive transport element" of the Mason-Pfizer simian retrovirus -
- Figure 22 illustrates the expression of the S protein after transfection of VeroE6 cells. Cell extracts were prepared 48 hours after transfection of VerEE6 cells by the pcDNA, pcDNA-S, pCI and pCI-S plasmids.
- VeroE6 cell extracts were prepared 8 hours after infection with SARS-CoV at a multiplicity of infection of 3. They were separated on an 8% acrylamide SDS gel and analyzed by western blot. using a rabbit anti-S polyclonal antibody and a peroxidase-coupled rabbit anti-IgG (H + L) polyclonal antibody (NA934V, Amersham). A molecular weight scale (kDa) is shown in the figure.
- SARS-CoV VeroE6 cell extract infected with SARS-CoV Moclc: uninfected cell control extract -
- Figure 23 illustrates the effect of CTE and WPRE sequences on S protein expression after VeroE6 and 293T cell transfection .
- Cell extracts were prepared 48 hours after transfection of VerEE ⁇ (A) or 293T (B) cells by the pcDNA, pcDNA-S, pcDNA-S-CTE, pcDNA-S-WPRE, pCI-S, pCI-S-CTE plasmids.
- SARS-CoV Extract of VeroE6 cells prepared 8 hours after infection with SARS-CoV at a multiplicity of infection of 3.
- Mock Control extract of uninfected VeroE6 cells -
- Figure 24 shows central defective lentiviral vectors with DNA flap for the expression of S of SARS-CoV.
- the cDNA of the S-protein of the SARS-CoV was cloned as a BamHI-XhoI fragment in the plasmid pTRIP ⁇ U-CMV containing a defective lentiviral vector TRIP to a central DNA flap (Sirven et al., 2001, Mol Ther. , 3: 438-448) to obtain plasmid pTRIP-S.
- the optimal expression cassettes consisting of the immediate / early promoter of the CMV virus, a splicing signal, the cDNA of the S and either of the CTE or WPRE post-transcriptional signals have been substituted for the EFl ⁇ -EGFP cassette of the defective lentiviral expression vector with central DNA FLAP TRIP ⁇ U3-EF1 ⁇ (Sirven et al., 2001, Mol.Ther., 3: 438-448) to obtain the plasmids pTRIP-SD / SA-S- CTE and pTRIP-SD / SA-S-WPRE.
- FIG. 26 relates to the analysis of polypeptide expression Ssol by cell lines transduced by the lentiviral vectors TRIP-SD / SA-Ssol-WPRE and TRIP-SD / SA-Ssol-CTE.
- the secretion of the Ssol polypeptide was sought in the supernatant of a series of cell clones isolated after transduction of FRhK-4 cells by the lentiviral vectors TRIP-SD / SA-Ssol-WPRE and TRIP-SD / SA-Ssol-CTE.
- Ssol A 8 0.5 and 0.125 ⁇ g of Ssol recombinant polypeptide purified by anti-FLAG affinity chromatography and gel filtration (G75) were separated on SDS gel with 8% polyacrylamide.
- FIG. 28 illustrates the influence of a splicing signal and the CTE and WPRE sequences on the efficiency of gene immunization using plasmid DNA encoding S of SARS-CoV A.
- mice Seven BALB / c mice were immunized twice at 4 week intervals using 50 ⁇ g of pCI, pcDNA-S, pCI-S, pcDNA-N and pCI-HA plasmid DNA.
- B. Groups of 6 BALB / c mice were immunized twice at 4-week intervals using 2 ⁇ g, 10 ⁇ g or 50 ⁇ g of pICI pCI plasmid DNA, pCI-S, pCI-S-CTE and pCI-S-WPRE.
- Immune sera taken 3 weeks after the second immunization were analyzed by indirect ELISA using a VeroE6 cell lysate infected with SARS-CoV as an antigen.
- Anti-SARS-CoV antibody titers are calculated as the reciprocal of the dilution producing a specific OD of 0.5 after revelation with peroxidase-coupled polyclonal anti-mouse IgG antibody (NA931 V, Amersham) and TMB (KPL).
- FIG. 29 shows the seroneutralization of SARS infectivity.
- FIG. 30 illustrates the immunoreactivity of the recombinant polypeptide
- Figure 31 shows the induction of antibodies to SARS-CoV after immunization with the recombinant Ssol polypeptide.
- Two groups of 6 mice were immunized 3 weeks apart with 10 ⁇ g of Ssol recombinant polypeptide (Ssol group) adjuvanted with aluminum hydroxide or, as a control, adjuvant alone (mock group)
- Ssol group Ssol recombinant polypeptide
- mouse group a control, adjuvant alone
- Three successive immunizations were carried out and the immune sera were taken 3 weeks after each of the three immunizations (IS1, IS2, IS3).
- Immune sera were pooled for each of the 2 groups by indirect ELISA using a VerAS6 cell lysate infected with SARS-CoV as an antigen.
- Anti-SARS-CoV antibody titers are calculated as the reciprocal of the dilution producing a specific OD of 0.5 after revelation with a polyclonal anti-mouse IgG antibody coupled with peroxidase (Amersham) and TMB (KPL) .
- FIG. 32 shows the nucleotide alignment of the sequences of the synthetic gene 040530 with the wild-type sequence of isolate 031589 of SARS-CoV. 1-3059 corresponds to nucleotides 21406-25348 of the isolate 031589 of SARS-CoV deposited at the CNCM under the number 1-3059 (SEQ ID NO: 4, plasmid pSRAS-S).
- S-040530 is the sequence of the synthetic gene 040530.
- FIG. 33 illustrates the use of a synthetic gene for the expression of S of SARS-CoV.
- Cell extracts prepared 48 hours after transfection of VeroE6 (A) or 293T (B) cells by plasmids pCI, pCI-S, pCI-S-CTE, pCI-S-WPRE and pCI-Ssynth were separated on an SDS gel. at 8% acrylamide and analyzed by western blot using a polyclonal anti-S rabbit antibody and a polyclonal anti-rabbit IgG (H + L) antibody coupled with peroxidase (NA934V, Amersham) .
- FIG. 34 presents a schematic of the construction of the recombinant vaccinia viruses VV-TG-S, VV-TG-Ssol, VV-TN-S and VV-TN-Ssol.
- sequences of the synthetic promoter 480 were then substituted for those of the 7.5 promoter by exchange of the NdeI-PstI fragment of the plasmids pTG186poly, pTG-S and pTG-Ssol to obtain the transfer plasmids pTN480, pTN-S and pTN-Solol .
- C Sequence of the synthetic promoter 480 as contained between the Ndel and PstI sites of the pTN series transfer plasmids. An Ascl site has been inserted to facilitate subsequent manipulations. The restriction sites as well as the promoter sequence are underlined
- the recombinant vaccinia viruses are obtained by double in vivo homologous recombination between the TK cassette of the transfer plasmids pTG and pTN series and the TK gene of the Copenhagen strain of vaccinia virus.
- SP predicted signal peptide (aa 1-13) with signalP v2.0 software
- TM predicted transmembrane region (aa 1196-1218) with TMHMM v2.0 software (Sonnhammer et al., 1998, Proc.of Sixth Int.Conf. on Intelligent Systems for Molecular Biology, pp 175-182, AAAI Press). It should be noted that the amino acids W1194 and PI 195 are possibly part of the transmembrane region with respective probabilities of 0.13 and 0.42.
- TK-L, TK-R left and right parts of the vaccinia virus thymidine kinase gene
- MCS multiple cloning site
- PE early promoter
- PL late promoter
- PL synth late synthetic promoter 480 -
- Cell extracts were prepared 18 hours after infection of CV1 cells with recombinant VV-vaccinia viruses.
- TG, VV-TG-S and VV-TN-S at a MOI of 2 (A).
- extracts of VeroE6 cells were prepared 8 hours after infection with SARS-CoV at a multiplicity of infection of 2.
- Cell extracts were also prepared 18 hours after infection of CV1 cells by recombinant vaccinia viruses VV-TG-S, VV-TG-Ssol, VV-TN, VV-TN-S and VV- TN-Sol (B). They were separated on 8% acrylamide SDS gels and analyzed by western blot using a rabbit anti-S polyclonal antibody and a coupled rabbit anti-IgG (H + L) polyclonal antibody.
- FIG. 37 shows the analysis of the Ssol polypeptide, purified by SDS polyacrylamide gel 10, 5 and 2 ⁇ l of recombinant Ssol polypeptide purified by anti-FLAG affinity chromatography were separated on SDS gel at a gradient of 4 to 15% polyacrylamide.
- the Ssol polypeptide as well as varying amounts of Molecular weight (MM) was revealed by silver nitrate staining (Gelcode SilverSNAP stain kit II, Pierce).
- FIG. 38 illustrates the immunoreactivity of the recombinant Ssol polypeptide produced by recombinant vaccinia virus VV-TN-Ssol with respect to sera from SARS patients.
- mice 39 shows the anti-SARS-CoV antibody response in mice after immunization with recombinant vaccinia virus.
- Groups of 7 BALB / c mice were immunized iv twice at 4-week intervals with 106 pfu of recombinant vaccinia virus VV-TG, VV-TG-HA, VV-TG-S, VV-TG- Ssol, VV-TN, VV-TN-S, VV-TN-Ssol.
- A Pools of immune sera collected 3 weeks after each of the two immunizations were performed for each of the groups and were analyzed by indirect ELISA using a VeroE6 cell lysate infected with SARS-CoV as an antigen.
- Anti-SARS-CoV antibody titers are calculated as the reciprocal of the dilution producing a specific OD of 0.5 after revelation with a peroxidase-coupled polyclonal anti-mouse IgG antibody (NA931V, Amersham) and TMB ( KPL).
- the seroneutralizing titer is calculated according to the method of Reed and Munsch as the inverse of the dilution neutralizing the infectivity of 2 out of 4 wells.
- the measles vector is a complete genome of the Schwarz vaccine strain of the measles virus (MV) in which an additional transcription unit has been introduced (Combredet, 2003, Journal of Virology, 77: 11546-11554).
- the expression of the additional open reading (ORF) phases is controlled by the cis-acting elements necessary for transgene transcription, cap formation, and polyadenylation, which have been copied from the elements present at the N junction.
- ORF additional open reading
- T7 T7 RNA polymerase promoter
- hh ribozyme hammerhead
- Figure 41 illustrates the expression of S protein by recombinant measles virus, analyzed by Western blot. Cytoplasmic extracts were prepared after infection of Vero cells by various passages of the MVSchw2-SARS-S and MVSchw2-SARS-Ssol viruses and the MWSchw wild-type virus as a control.
- Cell extracts in Laemmli deposition buffer were also prepared 8 hours after infection of VeroE6 cells with SARS-CoV at a multiplicity of infection of 3. They were separated on an 8% acrylamide SDS gel and analyzed by western blot using a polyclonal anti-S rabbit antibody and a polyclonal anti-rabbit IgG (H + L) antibody coupled to peroxidase (NA934V, Amersham). A molecular weight scale (kDa) is shown in the figure. Pn nth passage of the virus after coculture of 293-3-46 cells and
- Vero. SARS-CoV VeroE6 cell extract infected with SARS-CoV Mock: control extract of uninfected VeroE6 cells -
- Figure 42 shows the expression of S protein by recombinant measles viruses, analyzed by immunofluorescence Vero cells in monolayers on Glass slides were infected with MWSchw (A) wild-type virus or MVSchw2-SARS-S (B) and MVSchw2-SARS-Ssol (C) viruses.
- FIG. 43 illustrates the Western blot analysis of the immunoreactivity of rabbit sera directed against the El-12, E53-76 and M2-14 peptides.
- the 20047 rabbit was immunized with the El-12 peptide coupled to KLH.
- Rabbits 22234 and 22240 were immunized with peptide E53-76 coupled to KLH.
- Rabbits 20013 and 20080 were immunized with peptide M2-14 coupled to KLH.
- the antisera were analyzed by western blot using extracts of cells infected with SARS-CoV (B) or with extracts of cells infected with recombinant vaccinia virus expressing protein E (A). or M (C) of isolate 031589 of SARS-CoV.
- the immunoblots were revealed using an anti-rabbit IgG (H + L) conjugate coupled to peroxidase (NA934V, Amersham).
- the position of the E and M proteins is indicated by an arrow.
- a molecular weight scale (kDa) is shown in the figure.
- Isolated RNA was used as a template to amplify the cDNAs corresponding to the various open reading frames of the genome (ORF 1a, ORF1b, ORF-5, ORF-E, ORF-M, ORF-N (including ORF-13 and ORF-14), ORF3, ORF4, ORF7 to ORF1 1), and the 5 'and 3' non-coding ends.
- the sequences of primers and probes used for amplification / detection were defined according to the available nucleotide sequence of SARS-CoV.
- primers and probes are identified by: the letter S, followed by a letter that indicates the corresponding region of the genome (L for the 5 'end including ORFla and ORFlb; S, M and N for the ORFs -S, ORF-M, ORF-N, SE and MN for the corresponding intergenic regions), then optionally Fn, Rn, with n included between 1 and 6 corresponding to the primers used for the nested or nested PCR (IF + RI pair) for the first amplification, pair F2 + R2 for the second amplification, etc.), then / + / or / - / corresponding to a sense or antisense primer and finally positions of the primers with reference to the Genbank sequence AY27411.
- RNA extraction The RNAs were extracted using the Qlamp viral RNA mini extraction kit (QIAGEN) following the manufacturer's recommendations. More precisely: 140 ⁇ l of the sample and 560 ⁇ l of AVL buffer were mixed vigorously for 15 seconds, incubated for 10 minutes at room temperature and then briefly centrifuged at maximum speed. 560 ⁇ l of 100% ethanol was added to the supernatant and the mixture thus obtained was stirred very vigorously for 15 sec.
- cDNAs encoding Protein RNAs extracted from the sample were reverse transcribed using random sequence hexameric oligonucleotides (pdN6) to produce cDNA fragments.
- the sequence encoding S-glycoprotein of SARS-CoV was amplified as two overlapping DNA fragments: 5 'fragment (SARS-Sa, SEQ ID NO: 5) and 3' fragment (SARS-Sb, SEQ ID NO: 6), performing two successive amplifications using nested primers.
- RNA 5 .mu.l
- HO ppi 3.5 .mu.l
- 5X reverse transcriptase buffer 4 .mu.l
- 5 mM dNTPs 2 ⁇ l
- pdN6 100 ⁇ g / ml (4 ⁇ l)
- RNasin 40 IU / ⁇ l 0.5 ⁇ l
- reverse transcriptase AMV-RT 10 IU / ⁇ l
- PROMEGA 1 ⁇ l
- the reaction mixture of 50 ⁇ l containing: cDNA (2 ⁇ l), 50 ⁇ M primers (0.5 ⁇ l), 10 X buffer (5 ⁇ l), 5 mM dNTPs (2 ⁇ l), Taq Expand High Fidelity, Roche (0.75 ⁇ l) ⁇ l) and H 2 O (39.75 ⁇ l) was amplified in a thermal cycler under the following conditions: an initial denaturation step at 94 ° C. for 2 min was followed by 40 cycles comprising: a denaturation step at 94 ° C.
- PCR amplification The products of the first PCR amplification (5 'and 3' amplicons) underwent a second PCR amplification step (nested PCR) under conditions identical to those of the first amplification, with the primer pairs S / F2 / + / 21406-21426 and S / R2 / - / 23454-23435, and S / F4 / + / 23322-23341 and S / R4 / - / 25348-25329 respectively for the amplicon 5 'and the amplicon 3 '. ).
- Sb The amplicons Sa (5 'end) and Sb (3' end) thus obtained were purified using the QIAquick PCR purification kit (QIAGEN), following the manufacturer's recommendations, and then they were cloned into the PCR2 vector. .1-TOPO (Invitrogen kit), to give the plasmids called SARS-S1 and SARS-S2.
- the plasmid called SARS-S1
- SARS-S1 was deposited under No. 1-3020, on May 12, 2003, with the National Collection of Cultures of Microorganisms, 25 rue du Dondel Roux, 75724 Paris Cedex 15; it contains a 5 'fragment of the S gene sequence of the strain of SARS-CoV resulting from the sample indexed under No. 031589, as defined above, which fragment designated Sa corresponding to the nucleotides of positions 21406 to 23454 (SEQ ID NO: 5), with reference to Genbank sequence AY274119.3 Tor2.
- the plasmid, called TOP10F'-SARS-S2 was deposited under the No.
- SARS-S plasmid
- the insert contained in this plasmid was sequenced as above, using the primers as defined above. above for fragments Sa and Sb.
- the cDNA sequences of the insert and of the amplicon encoding the S protein correspond respectively to the sequences SEQ ID NO: 4 and SEQ ID NO: 2 in the attached sequence listing, they encode the protein S (SEQ ID NO: 3).
- the sequence of the amplicon corresponding to the cDNA coding for the S protein of the SARS-CoV strain resulting from the sample no.
- 031589 has the following two mutations with respect to the corresponding sequences of the isolates Tor2 and Urbani respectively, the positions of the mutations being indicated with reference to the complete genome sequence of isolate Tor2 (Genbank AY274119.3): - g / t at position 23220; the alanine codon (gct) at position 577 of the amino acid sequence of the Tor2 protein S is replaced by a serine codon (tct), - c / t at position 24872: this mutation does not modify the amino acid sequence of protein S, and The plasmid, called SARS-S, was deposited under No.
- RNAs from the sampling 031589, extracted as above were subjected to an associated reverse transcription, during the same step (Titan One Step RT-PCR® Kit, Roche) , to a PCR amplification reaction, using the pairs of primers:
- RNAsin 40 IU / ⁇ l
- a second reaction mixture containing: 1 ⁇ l of RNA, 7 ⁇ l of H 2 Oppi, 5 ⁇ l of 5 ⁇ RT-PCR buffer and 0.5 ⁇ l of a mixture of The enzyme and the combined mixtures were incubated in a thermocycler under the following conditions: 30 min at 42 ° C, 10 min at 55 ° C, 2 min at 94 ° C followed by 40 cycles including a denaturation step at 94 ° C for 10 sec, a hybridization step at 55 ° C for 30 sec and an elongation step at 68 ° C for 45 sec, with 3 sec increment per cycle and finally a step of terminal elongation at 68 ° C for 7 min.
- the amplification products thus obtained (amplicons M and E) underwent a second PCR amplification (nested PCR) using the Expand High-Fi® kit, Roche), using the pairs of primers:
- the reaction mixture containing: 2 ⁇ l of the product of the first PCR, 39.25 ⁇ l of H 2 O ⁇ pi, 5 ⁇ l of 10 ⁇ buffer containing MgCl 2 , 2 ⁇ l of dNTP (5 mM), 0.5 ⁇ l of each of the primers ( 50 ⁇ M) and 0.75 ⁇ l of enzyme mixture was incubated in a thermocycler under the following conditions: a denaturation step at 94 ° C.
- the amplification products obtained corresponding to the cDNAs encoding the E and M proteins were sequenced as above, using the primers: S / E / F2 / + / 26082 and S / E / R2 / - / 26394 , S / M / F2 / + / 26330, S / M / R2 / - / 27078 and S / M / + / 26636-26655 and S / M / - / 26567-26548 primers. They were then cloned, as above, to give the plasmids called SARS-E and SARS-M.
- the DNA of these clones was then isolated and sequenced using the M13 forward and M13 reverse universal primers as well as the aforementioned S / M / + / 26636 and S / M / - / 26548 primers.
- the sequence of the amplicon representing the cDNA coding for the protein E (SEQ ID NO: 13) of the SARS-CoV strain resulting from the sample no. 031589 does not have differences with respect to the corresponding sequences of the isolates AY274119.3 -Tor2 and AY278741 -Urbani.
- the sequence of the protein E of the SARS-CoV strain 031589 corresponds to the sequence SEQ ID NO: 14 in the attached sequence listing.
- the plasmid called SARS-E, was deposited under No. 1-3046, on May 28, 2003, with the National Collection of Microorganism Cultures, 25 rue du Dondel Roux, 75724 Paris Cedex 15; it contains the cDNA sequence coding for the E protein of the strain of SARS-CoV resulting from the sample indexed under No. 031589, as defined above, which sequence corresponding to the nucleotides of positions 26082 to 26413 (SEQ ID NO : 15), with reference to Genbank sequence Accession No. AY274119.3.
- 031589 corresponds to the sequence SEQ ID NO: 17 in the attached sequence listing.
- the plasmid, called SARS-M was deposited under No. 1-3047, on May 28, 2003, at the National Collection of Cultures of Microorganisms, 25 rue du Dondel Roux, 75724 Paris Cedex 15; it contains the cDNA sequence coding for the M protein of the SARS-CoV strain resulting from the sample indexed under No. 031589, as defined above; which sequence corresponding to the nucleotides of positions 26330 to 27098 (SEQ ID NO: 18), with reference to the sequence Genbank Accession No. AY274119.3.
- ORF7 to ORF1 1 S / MN / F1 / + / 26898-26917 and S / MN / R1 / - / 28287-28266
- the pairs of primers used for the second amplification are:
- ORF3 and ORF4 S / SE / F2 / + / 25110-25129 and S / SE / R2 / - / 26244-26225 - ORF7 to ORF1 1: S / MN / F2 / + / 26977-26996 and S / MN /
- the conditions of the first amplification are the following: 45 min at 42 ° C, 10 min at 55 ° C, 2 min at 94 ° C followed by 40 cycles comprising a step of denaturation at 94 ° C for 15 sec, a hybridization step at 58 ° C for 30 sec and an elongation step at 68 ° C for 1 min, with 5 sec increment per cycle and finally a step of terminal elongation at 68 ° C for 7 min.
- the conditions of the nested PCR are as follows: a denaturation step at 94 ° C for 2 min was followed by 40 cycles including a denaturation step at 94 ° C for 20 sec, a hybridization step at 58 ° C for 30 sec and an elongation step at 72 ° C for 50 sec, with 4 sec increment per cycle and finally an end elongation step at 72 ° C for 7 min.
- the amplification products obtained corresponding to the cDNAs respectively containing the ORF3 and 4 and the ORF7 to 11 were sequenced using Primers: S / SE / + / 25363, S / SE / + / 25835, S / SE / - / 25494, S / SE / - / 25875, S / MN / + / 27839, S / MN / + / 27409 , S / MN / - / 27836 S / MN / - / 27799 and cloned as above for the other ORFs, to give the plasmids called SARS-SE and SARS-MN.
- the DNA of these clones was isolated and sequenced using these same primers and universal primers M13 sense and M13 antisense.
- the sequence of the amplicon representing the cDNA of the region containing the ORFs 3 and 4 (SEQ ID NO: 7) of the strain of SARS-CoV resulting from the sample no. 031589 has a nucleotide difference with respect to the corresponding sequence of isolate AY274119-Tor2.
- This mutation at position 25298 results in a modification of the amino acid sequence of the corresponding protein (ORF 3): in position 11, an arginine (AY274119-Tor2) is changed to glycine in the strain of SARS-CoV from sample n ° 031589.
- 031589 does not differ from the corresponding sequences of isolates AY274119-Tor2 and AY278741-Urbani.
- the sequences of the ORF7 to 11 of the SARS-CoV strain from the sample No. 031589 correspond respectively to the sequences SEQ ID NO: 22, 24, 26, 28 and 30 in the attached sequence listing.
- the plasmid called SARS-MN was deposited under No. 1-3125, on November 13, 2003, at the National Collection of Cultures of Microorganisms, 25th of Dr. Roux, 75724 Paris Cedex 15; it contains the cDNA sequence corresponding to the region between the ORF-M and the ORF-N of the strain of SARS-CoV resulting from the sample recorded under No.
- cDNA Encoding N Protein and Including ORF13 and ORF14
- the cDNA was synthesized and amplified as described above for fragments Sa and Sb. More precisely, the reaction mixture containing: 5 ⁇ l of RNA, 5 ⁇ l of H 2 O ppi 4 ⁇ l of 5X reverse transcriptase buffer, 2 ⁇ l of dNTP (5 mM), 2 ⁇ l of oligo 20T (5 ⁇ l ⁇ M), 0.5 ⁇ l of RNasin (40 IU / ⁇ l) and 1.5 ⁇ l of AMV-RT (10 IU / ⁇ l Promega) was incubated in a thermocycler under the following conditions: 45 min at 42 ° C.
- a first PCR amplification was carried out with primer pair S / N / F3 / + / 28023 and S / N / R3 / - / 29480.
- the reaction mixture as above for the amplification of the S1 and S2 fragments was incubated in a thermal cycler, under the following conditions: an initial denaturation step at 94 ° C for 2 min was followed by 40 cycles comprising a step denaturation at 94 ° C for 20 sec, a hybridization step at 55 ° C for 30 sec then an elongation step at 72 ° C for 1 min 30 sec with 10 sec further elongation at each cycle, then d a final step of elongation at 72 ° C for 5 min.
- the amplicon obtained at the first PCR amplification underwent a second PCR amplification step (nested PCR) with primer pairs S / N / F4 / + / 28054 and S / N / R4 / - / 29430 under conditions identical to those of the first amplification.
- 031589 was sequenced using the primers: S / N / F4 / + / 28054, S / N / R4 / - / 29430, S / N / + / 28468, S / N / + / 28918 and S / N / - / 28607 and cloned as above for the other ORFs, to give the plasmid called SARS-N .
- the DNA of these clones was isolated and sequenced using the M13 sense and M13 antisense universal primers, as well as S / N / + / 28468, S / N / + / 28918 and S / N primers. D / - / 28607.
- sequence of the amplicon representing the cDNA corresponding to the ORF-N and including the ORF13 and ORF14 (SEQ ID NO: 36) of the SARS-CoV strain resulting from the sampling No. 031589 does not have any differences with respect corresponding sequences of isolates AY274119.3-Tor2 and AY278741 -Urbani.
- sequence of the N protein of the SARS-CoV strain resulting from the sample No. 031589 corresponds to the sequence SEQ ID NO: 37 in the attached sequence listing.
- sequences of the ORFs 13 and 14 of the SARS-CoV strain resulting from the sampling No. 031589 respectively correspond to the sequences SEQ ID NO: 32 and 34 in the attached sequence listing.
- SARS-N The plasmid called SARS-N was deposited under No. 1-3048, on June 5, 2003, at the National Collection of Cultures of Microorganisms, 25 rue du Dondel Roux, 75724 Paris Cedex 15; it contains the cDNA coding for the N protein of the strain of SARS-CoV resulting from the sample indexed under No. 031589, as defined above, which sequence corresponding to the nucleotides of the positions 28054 to 29430 (SEQ ID NO: 38 ), with reference to Genbank sequence Accession No. AY274119.3.
- the mixture thus obtained is incubated for 45 minutes at 37 ° C. and then for 2 minutes at 65 ° C.
- the product obtained is amplified by a first PCR reaction using the primers: S / L / - / 225-206 and anchor 14T: 5'-
- an initial denaturation step at 94 ° C. for 2 min is followed by 10 cycles comprising a denaturation step at 94 ° C. for 10 sec, a hybridization step at 45 ° C. for 30 sec then an elongation step at 72 ° C for 30 sec and then 30 cycles comprising a denaturation step at 94 ° C for 10 sec, a hybridization step at 50 ° C for 30 sec and then an elongation step at 72 ° C for 30 sec, then a final step of elongation at 72 ° C for 5 min.
- the product of the first PCR amplification underwent a second amplification step using the primers: S / L / - / 204-185 and 14T anchor mentioned above under conditions identical to those of the first amplification.
- the amplicon thus obtained was purified, sequenced with the primer S / L / - / 182-163 and then cloned as above for the various ORFs, to give the plasmid called SARS- 5'NC.
- the DNA of this clone was isolated and sequenced using the universal primers M13 sense and M13 antisense and the primer S / L / - / 182-163 supra.
- the amplicon representing the cDNA corresponding to the 5'NC end of the strain of SARS-CoV resulting from the sample numbered under the number 031589 corresponds to the sequence SEQ ID NO: 72 in the attached sequence listing; this sequence does not differ from the corresponding sequences of the AY274119.3-Tor2 and AY278741 -Urbani isolates.
- the plasmid called SARS-5'NC was deposited under No.
- RNAs from the sample 031589, extracted as above, were subjected to reverse transcription, according to the following protocol: the reaction mixture containing: RNA (5 .mu.l), HO (5 .mu.l), 5X reverse transcriptase buffer (4 ⁇ l), 5 mM dNTP (2 ⁇ l), 5 ⁇ M Oligo 20T (2 ⁇ l), 40 ⁇ / ⁇ l RNasin (0.5 ⁇ l) and RT-AMV 10 IU / ⁇ l (1.5 ⁇ l) PROMEGA) was incubated in a thermocycler under the following conditions: 45 min at 42 ° C, 15 min at 55 ° C, 5 min at 95 ° C, then it was kept at + 4 ° C.
- the cDNA obtained was amplified by a first PCR reaction using primers S / N / + / 28468-28487 and anchor 14T above.
- the conditions of the amplification are as follows: an initial denaturation step at 94 ° C. for 2 min is followed by 10 cycles comprising a denaturation step at 94 ° C. for 20 sec, a hybridization step at 45 ° C.
- the product of the first PCR amplification underwent a second amplification step using primers S / N / + / 28933-28952 and anchor 14T above, under conditions identical to those of the first amplification.
- the amplicon thus obtained was purified, sequenced using the primer S / N / + / 29257-29278 and cloned as above for the various ORFs, to give the plasmid called SARS-3'NC.
- the DNA of this clone was isolated and sequenced using the universal primers M13 sense and M13 antisense and the primer S / N / + / 29257-29278 supra.
- the amplicon representing the cDNA corresponding to the 3'NC end of the strain of SARS-CoV resulting from the sample numbered 031589, corresponds to the sequence SEQ ID NO: 73 in the attached sequence listing.
- SARS-3'NC contains the cDNA sequence corresponding to the 3 'non-coding end of the genome of the strain of SARS-CoV resulting from the sample numbered under the 031589, as defined above, which sequence corresponding to that located between the nucleotide at position 28933 to 29727 (SEQ ID NO: 40), with reference to the Genbank sequence accession number AY274119.3, ends with a series of nucleotides a.
- ORF1a and ORF1b The amplification of the 5 'region containing the ORF1a and ORF1b of the SARS-CoV genome resulting from the sampling 031589 was carried out by performing RT-PCR reactions followed by PCRs nested according to the same principles as those previously mentioned. described for other ORFs.
- the amplified fragments are overlapping on several tens of bases, thus allowing the computer reconstruction of the complete sequence of this part of the genome. On average, the amplified fragments are two kilobases.
- Nested PCR an initial denaturation step at 94 ° C. for 2 min is followed by 35 cycles comprising: a denaturation step at 94 ° C. for 15 sec, a hybridization step at 60 ° C. for 30 sec and then a step of elongation to
- sequences of the LO to L12 fragments of the SARS-CoV strain obtained from the sample indexed under No. 031589, respectively, correspond to the sequences SEQ ID NO: 41 to SEQ ID NO: 54 in the attached sequence listing. Of these sequences, only that corresponding to the L5 fragments has a nucleotide difference with respect to the conespondant sequence of the AY278741-Urbani isolate.
- This t / c mutation at position 7919 results in a modification of the amino acid sequence of the conespondant protein, encoded by ORF 1a: at position 2552, a valine (codon gtt; AY278741) is changed to alanine (codon gct) in the strain of SARS-CoV 031589.
- no mutation was identified with respect to the conespondante sequence of isolate AY274119.3 -Urbani.
- the other fragments do not differ from the conjecting sequences of the Tor2 and Urbani isolates.
- EXAMPLE 2 Production and Purification of Recombinant N and S Proteins of the SARS-CoV Strain Derived from the Specimen Recorded Under the Number 031589 Whole N Protein and Two Polypeptide Fragments of the S Protein of the SARS-CoV Strain From the Specimen Collection No. 031589 were produced in E. coli as fusion proteins comprising an N- or C-terminal polyhistidine tag.
- the N- and C-terminal hydrophobic sequences of the S protein were deleted whereas the ⁇ helix (positions 565 to 687) and the two coiled-coil units (positions 895 to 980 and 1155 to 1186) of the S protein have been preserved.
- These two polypeptides are consisting of: a long fragment (S L ) corresponding to positions 14 to 1193 of the amino acid sequence of protein S and a short fragment (Se) corresponding to positions 475 to 1193 of the amino acid sequence of protein S.
- Plasmids SARS-N and SARS-S were used as the template and the following oligonucleotides as primers: 5'-CC ⁇ ATATGTCTGATAATGGACCCCAATC AAAC-3 '(N sense, SEQ ID NO: 55) 5'-CCCCCGGGTGCCTGAGTTG AATC AGC AG AAGC-3' (N antisense, SEQ ID NO: 56) 5'-CCCATATGAGTGACCTTGACCGGTGCACCAC-3 '(S c sense, SEQ ID NO: 57) 5' -CCCATATGAAACCTTGCACCCCACCTGCTC-3 '(S L direction, SEQ ID NO: 58) 5'-CCCCCGGGTTTAATATATTGCTCATATTTTCCC -3 '(S c and S antisense L , SEQ ID NO: 59).
- the sense primers introduce an Ndel (underlined) site whereas the antisense primers introduce an XmaI or SmaI (underlined) site.
- the 3 amplification products were purified on a column (QIAquick PCR Purification Kit, QIAGEN) and cloned into an appropriate vector.
- the purified plasmid DNA of the 3 constructs was verified by sequencing and digested with the NdeI and XmaI enzymes.
- the 3 fragments corresponding to the N, S and Se cDNAs were purified on agarose gel and then inserted into the plasmids pIVEX2.3MCS (C-terminal polyhistidine label) and pIVEX2.4d (N-terminal polyhistidine label) previously digested by the same enzymes.
- the 6 expression vectors thus obtained (pIV2.3N, pIV2.3S c , pIV2.3S L , pIV2.4N, pIV2.4Sc also called pIV2.4S ⁇ , PIV2.4SL) were then used, on the one hand to test the expression of proteins in-vitro, and on the other hand to transform bacterial strain BL21 (DE3) pDIA17 (NOVAGEN).
- constructs encode proteins whose expected molecular mass is: pIV2.3N (47174 Da), pIV2.3S c (82897 Da), pIV2.3S L (132056 Da), pIV2.4N (48996 Da), pIV2 .4S ⁇ (81076 Da) and ⁇ IV2.4S L (133877 Da).
- Bacteria transformed with pIV2.3N were deposited at the CNCM on October 23, 2003, under the number 1-3117, and bacteria processed by pIV2.4S ⁇ were filed at the CNCM on October 23, 2003, under number 1-3118.
- N protein is very well produced in this bacterial system ( Figure 2) and is found mainly in a soluble fraction after lysis of bacteria.
- the long version of S (S) is very little produced and completely insoluble ( Figure 3).
- the short version (Se) also has a very low solubility, but a much higher expression rate than the long version.
- the construct Se fused to a polyhistidine label in the C-terminal position has a smaller size than expected. An immunodetection experiment with an anti-polyhistidine antibody showed that this construct was incomplete.
- the cells were recovered by centrifugation (10 min at 5000 rpm), resuspended in the lysis buffer (50 mM NaH 2 PO, 0.3 M NaCl, 20 mM imidazole pH 8 containing the mixture of Complete Protease Inhibitors®, Roche), and lysed by the French Press (12000 psi). After centrifugation of the bacterial lysate (15 min at 12000 rpm), the supernatant (50 ml) was deposited at a flow rate of 1 ml / min on a column (15 ml) of metal chelation (Ni-NTA superflow, Qiagen), balanced by the lysis buffer.
- the lysis buffer 50 mM NaH 2 PO, 0.3 M NaCl, 20 mM imidazole pH 8 containing the mixture of Complete Protease Inhibitors®, Roche
- the N protein was eluted with an imidazole gradient (20-250 mM) in 10 column volumes.
- the fractions containing the N protein were pooled and analyzed by polyacrylamide gel electrophoresis under denaturing conditions followed by staining with Coomassie blue.
- the results illustrated in FIG. 5 show that the protocol used makes it possible to purify the N protein with a very satisfactory homogeneity (95%) and an average yield of 15 mg of protein per liter of culture.
- the pellet was resuspended in 25 ml of lysis buffer containing 2% Triton XI 00 and 10 mM ⁇ -mercaptoethanol, and then centrifuged for 20 min at 12000 rpm. The pellet was resuspended in 10 mM Tris-HCl buffer containing 7 M urea, and gently stirred for 30 min at room temperature.
- Example 3 Immunodominance of Protein N The reactivity of the antibodies present in the serum of patients suffering from atypical pneumonitis caused by the SARS-associated coronavirus (SARS-CoV), with respect to the various proteins of this virus, was analyzed by western-blot under the conditions described below. 1) Material a) lysate of cells infected with SARS-CoV Vero E6 cells (2x10 6 ) were infected with SARS-CoV
- the serum referenced at the National Reference Center for Influenza Viruses (North Region) under N ° 20033168 is that of a French patient suffering from atypical pneumonitis caused by SARS-CoV collected at day 38 after early symptoms the diagnosis of SARS-CoV infection was made by nested RT-PCR and quantitative PCR. t> 2 ) .serums . complex proteins . S sera are those produced from recombinant proteins N and Se (Example 2), according to the immunization protocol described in Example 4; it is the rabbit serum PI 3097 (anti-N serum) and rabbit serum PI 1135 (anti-S serum).
- 20033168 reacts strongly with N and much weaker with S of SARS-CoV, since the 35 and 55 kDa polypeptides are revealed as intense bands for 1/300, 1/1000 and 1/3000 dilutions of antiserum while the 200 kDa polypeptide is only weakly revealed for a 1/300 dilution. It can also be noted that no other SARS-CoV polypeptide is detected for dilutions greater than 1/300 of the 20033168 serum. This experiment indicates that the SARS-CoV N-specific antibody response dominates the antibody responses. specificity of the other SARS-CoV polypeptides and in particular the antibody response directed against the glycoprotein S. It indicates an immunodominance of the nucleoprotein N during human infections by the SARS-CoV.
- Example 4 Preparation of Monospecific Polyclonal Antibodies Directed Against SARS-Associated Coronavirus-Associated N and S Proteins (SARS-CoV) 1) Material and Method Three rabbits (P13097, P13081, P13031) were immunized with the purified recombinant polypeptide corresponding to the entire nucleoprotein (N), prepared according to the protocol described in Example 2. After a first injection of 0.35 mg per rabbit of protein emulsified in Freund's complete adjuvant (intradermal route), the animals received 3 booster injections at 3 and then 4 weeks apart, 0.35 mg of recombinant protein emulsified as incomplete Freund's adjuvant.
- Three rabbits (PI 1135, PI 3042, PI 4001) were immunized with the recombinant polypeptide corresponding to the short fragment of the protein S (Se), produced as described in Example 2.
- the animals received 4 intradermal injections at 3-4 week intervals of an inclusion body preparation corresponding to 0.5 mg of recombinant protein emulsified in vitro. Freund's incomplete adjuvant.
- the first 3 injections were carried out with an inclusion body preparation prepared according to the protocol described in Example 2, while the fourth injection was carried out with an inclusion body preparation which were prepared according to the described protocol.
- Example 2 Example 2 and then purified on a sucrose gradient and washed in 2% Triton XI 00.
- a pre-immune serum (pi) was prepared before the first immunization and an immun-serum (LS.) 5 weeks after the fourth immunization.
- LS. immun-serum
- a first step the reactivity of the sera was analyzed by ELISA test with respect to recombinant protein preparations similar to those used for the immunizations; the ELISA tests were carried out according to the protocol and with the reagents as described in example 6.
- rabbit serum PI 1135 mainly recognizes a polypeptide whose apparent molecular mass (180-220 kDa according to the experiments) is compatible with a glycosylated form of S (1255 residues, unglycosylated polypeptide chain of 139 kDa), as well as lighter polypeptides, which presumably represent truncated forms and / or non-glycosylated S.
- all these experiments demonstrate that recombinant polypeptides expressed in E. coli and corresponding to the N and S proteins of SARS-CoV make it possible to induce in the animal polyclonal antibodies capable of recognizing the native forms of these proteins. .
- Example 5 Preparation of Monospecific Polyclonal Antibodies Directed Against SARS-Associated Coronavirus (SARS-CoV) M and E Proteins 1) Analysis of M and E Protein Structure a) Protein E Structure of SARS-Protein E CoV (76 amino acids) was analyzed in silico, using various software such as SignalP v1.1, NetNGlyc 1.0, THMM 1.0 and 2.0 (Krogh et al., 2001, J. Mol Biol., 305 (3)). ): 567-580) or TOPPRED (von Heijne, 1992, J. Mol Biol 225, 487-494).
- this non-glycosylated polypeptide is a type 1 membrane protein, containing a single transmembrane helix (aa 12-34 according to THMM), and the major part of the hydrophilic domain (42 residues) is localized to the membrane. C-terminus and presumably within the viral particle (endodomain).
- MYSFVSEETGT L
- SEQ ID NO: 70 the probability associated with the transmembrane location of the residue 12 is intermediate (0.56 according to THMM 2.0).
- the ectodomain of M probably corresponds to residues 2 to
- E53-76 KPTVYVYSRV KNLNSSEGVP DLLV, SEQ ID NO: 71
- KLH Keyhole Limpet Hemocyani ⁇
- MBS m-maleimido-benzoyl-N-hydroxysuccinimide ester
- Two rabbits were immunized with each of the conjugates, following the following immunization protocol: after a first injection of 0.5 mg of peptide coupled to KLH and emulsified in complete Freund's adjuvant (intradermal route), the animals receive 2 at 4 booster injections at 3 or 4 week intervals of 0.25 mg peptide coupled to KLH and emulsified with Freund's incomplete adjuvant.
- a pre-immune serum (pI) was prepared prior to the first immunization and an immune serum (LS) was prepared 3 to 5 weeks after the booster shots.
- the reactivity of the sera was analyzed by western blot using extracts of cells infected with SARS-CoV (FIG.
- the antiserum of rabbit 20047 immunized with the KLH-E1-12 conjugate, recognizes a polypeptide present in the extracts of cells infected with the virus VV-TG-E, whose apparent molecular weight is compatible with that of protein E (FIG. 43A).
- the peroxidase-labeled anti-human IgG conjugate (reference 209-035-098, JACKSON) diluted 1/18000 is then added and the plates are incubated for 1 h at 37 ° C.
- the chromogen (TMB) and the substrate (H 0 2 ) are added and the plates are incubated for 30 min at room temperature, protected from light. The reaction is then annealed and the absorbance at 450 nm is measured using an automatic reader.
- Chromogenic R9, RIO ankle solution commercially available reagents marketed by
- Bio-Rad (eg Platelia pylori kit, ref 72778) b) Procedure Dilute the sera to 1/200 in the sample diluent Dispense 100 ⁇ l / well Incubation lh at 37 ° C 3 washes in LAVAGE R2 solution 10x diluted 10 times in demineralized water (the., washing solution IX) Dispense lOO ⁇ L of conjugate (50x conjugate to be diluted extemporaneously in the conjugated diluent provided) Incubation lh at 37 ° C 4 washes in washing solution IX distribute 200 ⁇ L / well of revealing solution (to be diluted extemporaneously eg 1 mL of R9 in 10 mL of R8) Incubation 30 min at room temperature in the dark anastate the reaction with 100 ⁇ l / well of RIO READ at 450 / 620nm The results can be interpreted by taking a serum THRESHOLD giving a response beyond which the sera tested will be
- the plates are sensitized with a solution of protein N at 1 ⁇ g / ml in a 10 mM PBS buffer, pH 7.2, phenol red at 0.25 ml / l. 100 ⁇ L of solution are deposited in the wells and allowed to incubate at room temperature overnight.
- This ProtN POD conjugate is used at a concentration of 2 ⁇ g / ml in serum / conjugate diluent.
- Other solutions R2 washing solution, TMB R8 revealing solutions, diluent, chromogenic R9, RIO ankle solution: reagents marketed by Bio-Rad (ex kit platelia pylori ref 72778).
- reaction plate Transfer 100 ⁇ L of mixture / well into the reaction plate. Incubation 37 ° C.” 5 washes in Wash solution R2 10x previously diluted 10 times in demineralized water (-> washing solution 1x). distribute 200 ⁇ L / well of the revealing solution (to be extemporaneously diluted eg 1 mL of R9 in 1 R8 OmL)
- RT-PCR analyzes were performed by RT-PCR nested BNI, LC Artus and LC-N on nasal or pharyngeal swabs; POS means that at least one sample was found positive in this patient.
- POS means that at least one sample was found positive in this patient.
- the reactivity of the sera in the ELISA using a lysate of cells infected with SARS-CoV was classified as highly reactive (+++), highly reactive (++), reactive (+) and function of the OD value obtained at the dilutions tested.
- Example 8 Detection of the coronavirus associated with SARS-CoV by SAR-PCR 1
- the design of the primers and probes was carried out from the genome sequence of the SARS-CoV strain derived from the specimen collected under the number 031589, using the program "Light Cycler Probe Design (Roche)".
- - series 1 SEQ ID NO: 60, 61, 64, 65
- antisense primer N / - / 28774: 5'-CAG TTT CAC CAC CTC C-3 '[28774-28759] - probe 1: 5'-GGC ACC CGC AAT CCT AAT AAC AAT GC-fluorescein 3' [28561- 28586] Probe 2: 5 'Red705 -GCC ACC GTG CTA CAA CTT CCT-Phosphate [28588-28608] - Series 2 (SEQ ID NO: 62, 63, 66, 67)
- antisense primer N / - / 28702: 5'-AAT TAC CGC GAC TAC G-3 '[28702-28687] - probe 1: SARS / N / FL: 5'-ATA CAC CCA ACCA ACA TTG GC - fluorescein 3 '[28541-28563]
- This synthetic RNA was prepared by in vitro transcription using phage T7 RNA polymerase of a DNA template obtained by linearization of the plasmid SARS-N with the BamHI enzyme. After removal of the DNA template by digestion with DNAse 1, the synthetic RNAs are purified by phenol-chloroform extraction followed by two successive precipitations of ammonium acetate and isopropanol. They are then quantified by measuring the absorbance at 260 nm and their quality is controlled by the absorbance ratio at 260 and 280 nm as well as by agarose gel electrophoresis.
- the concentration of the synthetic RNA preparation used for these studies is 1.6 mg / ml, which corresponds to 2.1.10 15 copies / ml of RNA.
- Decreasing amounts of synthetic RNA were amplified by RT-PCR using the "Superscript TM One-Step RT-PCR Kit with Platinum® Taq" and primer pairs # 1 (N / + / 28507, N / - / 28774) ( Figure 1A) and No. 2 (N / + / 28375, N / - / 28702) ( Figure 1B), following the indications of the supplier.
- the amplification conditions used are as follows: the cDNA was synthesized by incubation for 30 min at 45 ° C., 15 min at 55 ° C.
- the viral RNA of a stock of SARS-CoV grown on Vero E6 cells was extracted using the "Qiamp viral RNA extraction" kit (Qiagen), diluted to 0.05 ⁇ 10 -4 and analyzed by RT-PCR in real time according to the protocol described above, the analysis presented in Figure 12 shows that this virus stock contains 6.5.10 9 genomes -equivalents / ml (geq / ml), which is all is similar to the value of 1.0.10 10 geq / ml measured using the kit "RealArt HPA- Coronavirus LC RT PCR Reagents" marketed by Artus.
- Step One RT-PCR Coupled "SNE” The Invitrogen Kit "Super Script TM One-Step RT-PCR with Platinum®
- Taq has been used, but Roche Boehringer's "Titan” kit can be substituted with similar results.
- Oligonucleotides - SNE-S1 5 'GGT TGG GAT TAT CCA AAA TGT GA 3'
- RNAsin N2511 N2515
- Synthetic RNAs served as a positive control.
- 10 3 , 10 2 and 10 copies of synthetic R S NE RNA were amplified in each experiment.
- RT-real time PCR were compared to 121 suspected SARS respiratory samples from the French hospital in Hanoi, Vietnam, produced between the 4 th and 17 th day after the start of symptoms. Among these samples, 14 had been found positive in a first test using the nested RT-PCR method targeting the ORF1b (encoding the replicase) as initially described by the
- the different tests compared in this study are: the quantitative RT-PCR method according to the invention, with the primers and N "series 2" probe described above (Light Cycler N column), the nested RT-PCR test targeting the RNA polymerase gene described above, developed by the CDC, the BNI and the Pasteur Institute (RT-PCR nested CDC / IP), - the reference ARTUS kit "HPA Corona LC RT-PCR Kit” 5601-02 ", which is a real-time RT-PCR assay targeting the ORFlb gene, the BNI-nested RT-PCR assay, also targeting the RNA polymerase gene, mentioned above.
- the SARS-linked coronavirus RNA polymerase gene which is targeted in most currently available assays, can recombine with that of other non-SARS-related coronaviruses.
- the use of a test exclusively targeting this gene could then lead to the obtaining of false negatives.
- the quantitative RT-PCR test according to the invention does not target the same genomic region as the ARTUS kit, since it targets the gene coding for the N protein.
- the hybridoma producing this antibody has been deposited in the National Collection of Cultures of Microorganisms (CNCM) of the Patseur Institute (Paris, France) on 1 December 2004 under the number 1-3331. This same epitope is also recognized by a rabbit serum (anti-N polyclonal) obtained by conventional immunization using this same protein N. 2. Monoclonal antibodies specific for a major linear epitope located in central position (position 217-224 , sequence: ETALALL); Representatives of this group are the monoclonal antibodies 87 and 166. The hybridoma producing the antibody 87 has been deposited at CNCM on December 1, 2004 under the number 1-3328. 3.
- Monoclonal antibodies specific for a major linear epitope located at the C-terminal position (position 403-408, sequence: DFFRQL), the representatives of this group are the antibodies 28, 57 and 143.
- the hybridoma producing the antibody 57 was deposited with the CNCM on December 1, 2004 under the number 1-3330. 4.
- Monoclonal antibodies specific for a discontinuous, conformational epitope This group of antibodies does not recognize any of the peptides covering the N protein sequence, but react strongly on the undenatured natural protein.
- the representative of the latter group is the antibody 86.
- the hybridoma producing this antibody was deposited with the CNCM on December 1, 2004 under the number 1-3329. Table VIII below summarizes the epitope mapping results obtained:
- these antibodies do not show any reactivity with ELISA and / or WB, with respect to the N protein of human coronavirus 229 E.
- EXAMPLE 10 Combinations of Monoclonal Antibodies for Development of a sensitive and specific immunocapture test of N viral antigen in the serum or biological fluids of patients contaminated with SARS Co V
- the antibodies listed below were selected because of their very particular properties for additional study of capture and detection of the N viral protein, in the serum of the subjects or patients. These antibodies were produced in mouse ascites, purified by affinity chromatography and used alone or in combination as capture antibodies, and as signal antibodies.
- conjugates were purified by exclusion chromatography and kept concentrated (concentration between 1 to 2 mg / ml) in the presence of 50% glycerol and at -20 ° C. They are diluted for their use in the tests at the final concentration of 1 or 2 ⁇ g / ml in PBS buffer (pH 7.4) supplemented with 1% BSA.
- PBS buffer pH 7.4
- Other reagents Negative human sera for all serum markers of HIV, HBV, HCV and THLV
- Solid phase (Acms 86, 166 and 87 central region and conformational epitope): mixed conjugate antibody 28 (C-ter) and 87 (central) 5. Combination G / 87
- the first 4 combinations have equivalent and reproduced performances, superior to the other combinations used (as for example the combination G / 87).
- a monoclonal antibody can be replaced by another antibody recognizing the same epitope.
- the detection limit of these 4 experimental assays is antigen dilution to negative serum 1: 62500. Rapid extrapolation suggests the detection of less than 10 3 infectious particles per ml of sera.
- the most suitable antibodies for the capture of the native viral nucleoprotein are the antibodies specific for the central region and / or a conformational epitope, both being antibodies also selected for their strong affinity for the native antigen.
- the antibodies to be retained in priority for the detection of the antigens fixed on the solid phase are the complementary antibodies specific for a dominant epitope in C-ter region. The use of any other complementary antibody, but specific to epitopes located in the N-ter region of the protein leads to average or poor results.
- Example 11 Eukaryotic Expression Systems of Spike Protein (S) of SARS-Associated Coronavirus (SARS-CoV)
- CoV was amplified by PCR using the 5'-ATAGGATCCA CCATGTTTAT TTTCTTATTA TTTCTTACTC oligonucleotides TCACT-3 'and 5'-ATACTCGAGTT. ATGTGTAATG TAATTTGACA CCCTTG-3 'from the plasmid pSARS-S (CNCM No. 1-3059) then inserted between the BamHl and XhoI sites of the plasmid pTRIP ⁇ U3-CMV containing a TRIP lentiviral vector (Sirven, 2001, Mol. Ther., 3, 438-448) to obtain the plasmid pTRIP-S.
- the BamHl and XhoI fragment containing the S cDNA was then subcloned between BamH1 and XhoI of the eukaryotic expression plasmid pcDNA3.1 (+) (Clontech) to obtain the pcDNA-S plasmid.
- the Nhe I and Xho I fragment containing the S cDNA was then subcloned between the corresponding sites of the pCI expression plasmid (Promega) to obtain the plasmid pCI-S.
- WPRE sequences of the Woodchuck Hepatitis virus posttranscriptional regulatory element ("Woodchuck Hepatitis Virus" element) and the constitutive transport element (CTE) sequences of the Mason-Pfizer simian retrovirus were inserted into each of the two pcDNA plasmids. S and pCI-S between the XhoI and XbaI sites to obtain respectively the pcDNA-S-CTE, pcDNA-S-WPRE, pCI-S-CTE and pCI-S-WPRE plasmids (FIG. 21).
- the plasmid pCI-S-WPRE was deposited at the CNCM on November 22, 2004, under the number 1-3323.
- cell extracts were prepared in Laemmli deposition buffer, separated on an 8% SDS gel of polyacrylamide and then transferred onto a PVDF membrane. (BioRad).
- the detection of this immunoblot (“western blot") was carried out using a rabbit anti-S rabbit polyclonal serum (rabbit immune serum Pl 135: see example 4 above) and polyclonal antibodies. donkey directed against rabbit IgG and coupled with peroxidase (NA934V, Amersham). The fixed antibodies were revealed by luminescence using the ECL + kit (Amersham) and Hyperfilm MP autoradiography films (Amersham). This experiment (FIG.
- the plasmid pcDNA-S does not make it possible to direct the expression of the S of SARS-CoV at detectable levels while the plasmid pCI-S allows a weak expression, close to the limit of detection. , which can be highlighted when the film is overexposed. Similar results were obtained when the expression of S was sought by immunofluorescence (not shown). This inability to detect efficient expression of S can not be attributed to the detection techniques used since the S protein can be demonstrated at the expected size (180 kDa) in an extract of cells infected with SARS-CoV or in an extract of VeroE6 cells infected with recombinant vaccinia virus VV-TF7.3 and transfected with the plasmid pcDNA-S.
- VV-TF7.3 virus expresses phage T7 RNA polymerase and allows the cytoplasmic transcription of an uncapped RNA capable of being efficiently translated.
- This experiment suggests that the expression defects described above are due to an intrinsic inability of the S cDNA to be efficiently expressed when the messenger RNA transcription step is performed at the nuclear level.
- the effect of the CTE and WPRE signals on the expression of S was sought after transfection of VeroE6 cells (FIG. 23A) and 293T (FIG. 23B) and according to a protocol similar to that described above.
- the levels of expression are indicated according to an arbitrary scale where the value of 1 represents the level measured after transfection of the plasmid pCI-S. Two independent experiments were performed for each of the two cell types. In Experiment 1 on VeroE6 cells, the transfections were performed in duplicate and the results are indicated in the form of averages and standard deviations of the measured excretion levels.
- Transient co-transfection according to Zennou et al (2000, Cell, 101: 173-185) of this plasmid, an encapsidation plasmid (p8.2) and an envelope glycoprotein expression plasmid VSV G (pHCMV-G) in 293T cells allowed the preparation of retroviral pseudoparticles containing the TRIP-S vector and G envelope protein pseudotyped. These pseudotyped TRIP-S vectors were used to transduce 293 T cells. and FRhK-4: no expression of the S protein could be detected by western blot and immunofluorescence in the transduced cells (data not shown).
- the optimal expression cassettes consisting of the CMV immediate / early promoter, a splicing signal, the S cDNA and either of the post-transcriptional signals WPRE or CTE described above were then substituted for the EFl ⁇ -EGFP cassette of the defective lentiviral expression vector with central DNA FLAP TRIP ⁇ U3-EF1 ⁇ (Sirven et al, 2001, Mol Ther, 3: 438-448) (FIG. These substitutions were carried out by a series of successive subcloning of the S expression cassettes which were excised from the plasmids pCT-S-CTE (BglII-Apal) or respectively pCI-S-WPRE (BglII-SalI) and then inserted.
- Pseudotyped vectors were produced according to Zennou et al (2000, Cell, 101: 173-185) and used to transduce 293T (10,000 cells) and FRhK-4 cells (15,000 cells) in a series of 5 successive cycles of transduction with a vector amount corresponding to 25 ng (TRIP-SD / SA-S-CTE) or 22 ng TRIP-SD / SA-S-WPRE) of p24 per cycle.
- the transduced cells were cloned by limiting dilution and a series of clones were analyzed for SARS-CoV S expression. qualitatively by immunofluorescence (data not shown), then quantitatively by western blot (FIG. 25) using a polyclonal anti-S rabbit serum.
- the TRIP-SD / SA-S-CTE and TRIP-SD / SA-S-WPRE vectors make it possible to obtain stable clones of FRhK-4 cells and similarly 293T expressing the S of SARS-CoV, while tests with the "basic" TRIP-S vector were unsuccessful, demonstrating the need for a splicing signal as well as one or other of the CTE and WPRE sequences for the obtaining stable cell clones expressing the S protein.
- these modifications of the TRIP vector (insertion of a splicing signal and of a post-transcriptional signal such as CTE and WPRE) could prove to be interesting for improving expression.
- other cDNA than that of S.
- a DNA fragment coding for S-ectodomain of SARS-CoV was amplified by PCR using the 5'-ATAGGATCCA CCATGTTTAT TTTCTTATTA TTTCTTACTC TCACT-3 'oligonucleotides and 5'-ACCTCCGGAT TATATATATT GCTCATATTT TCCCAA-3 'from the plasmid pcDNA-S, then inserted between the unique BamHl and BspEl unique sites of a modified eukaryotic expression plasmid pcDNA3.1 (+) (Clontech) containing between its sites BamH1 and Xho1 the sequence of the FLAG tag: // GGATCC ... nnn ... TCC GGA GAT TAT AAA GAT GAC GAC GAT AAA TAA BamHl SGDYKDDDD ter
- CTCGAG // XhoI The NheI-XhoI and BamHI-XhoI fragments, containing the S cDNA, were then excised from the pcDNA-Ssol plasmid, and subcloned between the corresponding sites of the pTRIP-SD / SA-S-CTE plasmid. and plasmid pTRIP-SD / SA-S-WPRE, respectively, to obtain plasmids pTRIP-SD / SA-Ssol-CTE and pTRIP-SD / SA-Ssol-WPRE, deposited at the CNCM, on 1 December 2004 under the numbers 1-3337 and 1-3335, respectively.
- Pseudotyped vectors were produced according to Zennou et al. (2000, Cell, 101: 173-185) and used to transduce FRhK-4 cells (15,000 cells) in a series of 5 successive cycles of transduction (15,000 cells) with a vector amount of 24 ng (TRIP-SD). / SA-Sol-CTE) or 40 ng TRIP-SD / SA-Sol-WPRE) of p24 per cycle.
- the transduced cells were cloned by limiting dilution and a series of 16 clones transduced by TRIP-SD / SA-Ssol-CTE and 15 clones by TRIP-SD / SA-Ssol-WPRE were analyzed for the expression of the Ssol polypeptide.
- Table XI Analysis of Ssol polypeptide expression by cell lines transduced by the lentiviral vectors TRIP-SD / SA-Ssol-WPRE and TRIP-SD / SA-Ssol-CTE.
- the secretion of the Ssol polypeptide was sought in the supernatant of a series of cell clones isolated after transduction of FRhK-4 cells by the lentiviral vectors TRIP-SD / SA-Ssol-WPRE and TRIP-SD / SA-Ssol-CTE.
- the supernatants diluted 1:50 were analyzed by an ELISA-capture test S calif of SARS-CoV.
- the cell line secreting the highest amounts of Ssol polypeptide in the culture supernatant is the FRhK4-Ssol-CTE3 line. It was subjected to a second series of 5 cycles of transduction by the TRIP-SD / SA-Ssol-CTE vector under conditions similar to those described above and then cloned.
- the subclone secreting the highest amounts of Ssol was selected by a combination of Western blot and ELISA-capture analysis: this is the FRhK4-Ssol-30 subclone, which was deposited at the CNCM , November 22, 2004, under the number 1-3325.
- the FRhK4-Ssol-30 line allows the production and the purification in quantity of the recombinant polypeptide Ssol.
- the cells of the FRhK4-Ssol-30 line are seeded in a standard culture medium (DMEM without pyruvate containing 4.5 g / l of glucose and supplemented with with 5% FCS, 100 U / ml penicillin and 100 ⁇ g / ml streptomycin) in the form of a subconfluent monolayer (1 million cells per 100 cm 2 in 20 ml of medium).
- DMEM fetal
- FCS 100 U / ml penicillin and 100 ⁇ g / ml streptomycin
- the culture supernatant is taken after 4 to 5 days of incubation at 35 ° C. and 5% of CO 2 .
- the recombinant polypeptide Ssol is purified from the supernatant by the sequence of 0.1 ⁇ m polyethersulphone (PES) membrane filtration steps, concentration by ultrafiltration on a 50 kD cutoff PES membrane, affinity chromatography. on an anti-FLAG matrix eluting with a solution of FLAG peptide (DYKDDDDK) at 100 ⁇ g / ml in TBS (50 mM Tris pH 7.4, 150 mMNaCl) and then gel chromatography filtration in TBS on Sephadex G-75 beads (Pharmacia) .
- PES polyethersulphone
- the concentration of the purified recombinant Ssol polypeptide was determined by micro-BCA test (Pierce) and then its biochemical characteristics analyzed. 8% SDS gel analysis of silver nitrate-stained acrylamide shows a majority polypeptide with a molecular weight of about 180 kD and a degree of purity of 98%) (FIG. 27A). ). By SELDI-TOF mass spectrometry (Cyphergen), two main peaks are evidenced: they correspond to simply and doubly charged forms of a major polypeptide whose molecular mass is thus determined at 182.6 ⁇ 3.7 kD. ( Figures 27B and C).
- the recombinant polypeptide Ssol therefore consists of amino acids 14 to 1193 of the S protein of SARS-CoV fused at the C-terminal to an SGDYKDDDDK sequence containing the sequence of the FLAG label (underlined).
- the difference between the theoretical molar mass of the naked Ssol polypeptide (132.0 kD) and the actual molar mass of the mature polypeptide (182.6 kD) suggests that the Ssol polypeptide is glycosylated.
- a purified Ssol polypeptide preparation whose protein concentration has been determined by micro-BCA test makes it possible to produce a standard range.
- the FRhK4-Ssol-CT3 line secretes 4 to 6 ⁇ g / ml of Ssol polypeptide whereas the FRhK4-Ssol-30 line secretes 9 to 13 ⁇ g / ml of Ssol after 4 to 5 days of culture at confluence.
- the purification scheme presented above allows routine purification of 1 to 2 mg of Ssol polypeptide per liter of culture supernatant.
- BALB / c mice were immunized at 4 week intervals by injection into the tibialis anterior of a saline solution of 50 ⁇ g of pcDNA-S and pCI-S plasmid DNA and, as a control , with 50 ⁇ g of pcDNA-N plasmid DNA (directing the expression of the N of SARS-CoV) or of pCI-HA (directing the expression of influenza A / PR / 8/34 HA) and the immune sera collected 3 weeks after the 2nd injection.
- pcDNA-N plasmid DNA directing the expression of the N of SARS-CoV
- pCI-HA directing the expression of influenza A / PR / 8/34 HA
- TI peroxidase-coupled mouse anti-mouse IgG polyclonal antibody
- the plasmid pCI-S provided with a splicing signal allows induction antibodies in high titers (LOGATIA 3.7 ⁇ 0.2), which are about 60 times higher than those observed after injection of plasmid pcDNA-S (p ⁇ 10 "5).
- the effectiveness of posttranscriptional signals was studied by performing a dose-response study of anti-S antibody titres induced in BALB / c mice according to the amount of plasmid DNA used as immunogen (2 ⁇ g, 10 ⁇ g and 50 ⁇ g).
- the sera of probable cases of SARS tested were chosen on the basis of the results (positive or negative) of analysis of their specific reactivity with respect to the native SARS-CoV antigens by immunofluorescence test on VeroE6 cells infected with SARS-CoV and / or by indirect ELISA using as antigen a lysate of VeroE6 cells infected with SARS-CoV.
- the sera of these patients are identified by a serial number of the National Influenza Reference Center as well as the initials of the patient and the number of days since the onset of symptoms.
- Solid phases sensitized with the recombinant polypeptide Ssol were prepared by adsorption of a solution of purified Ssol polypeptide at 2 ⁇ g / ml in PBS in the wells of an ELISA plate, then the plates are incubated overnight at 4 ° C. and washed with PBS-Tween buffer (PBS, 0.1% Tween20). After saturation of the ELISA plates with a PBS-skimmed milk solution at 10% (weight / volume) and washing with PBS-Tween, the sera to be tested (100 ⁇ l) are diluted 1/400 in PBS-skimmed milk buffer.
- PBS-Tween buffer PBS, 0.1% Tween20
- Tween PBS, 3%> skim milk, 0.1%> Tween
- the plates are incubated for 1 h at 37 ° C.
- the peroxidase-labeled anti-human IgG conjugate ref NA933V, Amersham
- the chromogen (TMB) and the substrate H 2 O are added and the plates are incubated for 10 minutes in the dark.
- the reaction is stopped by adding an IN solution of H 3 PO 4 , then the absorbance is measured at 450 nm with a reference at 620 nm.
- the ELISA tests demonstrate that the recombinant Ssol polypeptide is specifically recognized by the serum antibodies of SARS patients collected in the middle or late phase of the infection (> 10 days after the onset of symptoms whereas it does not is significantly unrecognized by the serum antibodies of two patients (JLB and CWY) taken early in the infection (3 to 8 days after onset of symptoms) or by control sera from subjects without SARS.
- mice were immunized 3 weeks apart with 10 ⁇ g of recombinant polypeptide Ssol adjuvated with 1 mg of aluminum hydroxide (Alu-gel-S, Serva) diluted in PBS.
- Three successive immunizations were performed and the immune sera were taken 3 weeks after each of the immunizations (IS1, IS2, IS3).
- a group of mice received aluminum hydroxide alone according to the same protocol.
- the immune sera were pooled for each of the 2 groups by indirect ELISA using a VeroE6 cell lysate infected with SARS-CoV as an antigen and as a control, a lysate of uninfected VeroE6 cells.
- Anti-SARS-CoV antibody titers are calculated as the reciprocal of the dilution producing a specific OD of 0.5 after revelation by a peroxidase-coupled polyclonal anti-mouse IgG (H + L) antibody (NA931V, Amersham). ) and TMB supplemented with H 2 O (KPL).
- H + L peroxidase-coupled polyclonal anti-mouse IgG
- KPL H 2 O
- Immune sera were pooled for each of the 2 groups for their ability to seroneutralize the infectivity of SARS-CoV. 4 points of seroneutralization on FRhK-4 cells (100 TCID 50 of SARS-CoV) are carried out for each of the dilutions of reason 2 tested starting from 1/20.
- the seroneutralizing titer is calculated according to the method of Reed and Munsch as the inverse of the dilution neutralizing the infectivity of 2 out of 4 cups. This analysis shows that the antibodies induced in the mouse by the Ssol polypeptide are neutralizing: the observed titres are very high after 2 and then 3 immunizations (greater than 2560 and 5120 respectively, Table XIII).
- Table XIII Induction of antibodies directed against SARS-CoV after immunization with the recombinant polypeptide Ssol.
- the immune sera were pooled for each of the 2 groups for their ability to seroneutralize the 100 TCID50 infectivity of SARS-CoV on FRhK-4 cells. 4 points are made for each reason dilutions 2 tested from 1/20.
- the seroneutralizing titer is calculated according to the method of Reed and Munsch as the inverse of the dilution neutralizing the infectivity of 2 out of 4 wells.
- mice immunized with the Ssol polypeptide reach levels much higher than those observed by Yang et al. in mice (2004, Nature, 428: 561-564) and those observed by Buchholz in hamsters (2004, PNAS 101: 9804-9809), which respectively protect the mouse and hamster from SARS infection. CoV. It is therefore likely that the antibodies Neutralizers induced in mice after immunization with the Ssol polypeptide protect these animals against infection with SARS-CoV.
- Synthetic gene design A synthetic gene encoding the SRAS-CoV spike protein was designed from the isolate gene 031589 (plasmid pSARS-S, CNCM # 1-3059) to allow high levels of expression in mammalian cells and in particular in cells of human origin.
- the codon usage of the wild-type 031589 gene has been modified so as to approximate the bias observed in humans and to improve the translation efficiency of the corresponding mRNA - the overall GC content of the
- the gene was augmented to prolong the half-life of the corresponding mRNA - the patterns, possibly cryptic, likely to interfere with efficient expression of the gene were deleted (splice donor and acceptor sites, polyadenylation signals, highly rich (> 80%) or very poor ( ⁇ 30%>) in GC, repeated sequences, sequences involved in the formation of RNA secondary structures, TATA boxes) - a second STOP codon was added to allow efficient termination translation.
- CpG motifs have been introduced into the gene so as to increase its immunogenicity as a DNA vaccine.
- SEQ ID No: 140 An alignment of the synthetic gene 040530 with the wild-type sequence of isolate 031589 of SARS-CoV deposited at the CNCM. under the number 1-3059 (SEQ ID NO: 4, plasmid pSRAS-S) is shown in Figure 32.
- SEQ ID No: 140 was assembled from synthetic oligonucleotides and cloned between the KpnI and SacI sites of the plasmid pUC-Kana to give the plasmid 040530pUC-kana.
- the nucleotide sequence of the insert of plasmid 040530pUC-kana was verified by automatic sequencing (Applied).
- a KpnI-XhoI fragment containing the synthetic gene 040530 was excised from the plasmid 040530pUC-kana and subcloned between the NheI and XhoI sites of the expression plasmid pCI (Promega) to obtain the plasmid pCI-S SYNTH deposited at the CNCM. December 1, 2004 under the number 1-3333.
- a synthetic gene coding for the soluble form of the S protein was then obtained by fusing the synthetic sequences coding for the ectodomain of the protein S (amino acids 1 to 1193) to those of the tag (FLAG: DYKDDDDK) via a BspE1 linker encoding the dipeptide S G.
- a DNA fragment coding for the ectodomain S of SARS-CoV was amplified by PCR using oligonucleotides 5'-ACTAGCTAGC GGATCCACCA TGTTCATCTT CCTG -3 'and 5'-AGTATCCGGAC TTGATGTACT GCTCGTACTT GC-3 'from the plasmid 040530pUC-kana, digested with NheI and BspEl then inserted between the unique NheI and BspEl sites of the plasmid pCI-Ssol, to give the plasmid pCI-ScUBE, deposited at the CNCM December 1, 2004 under the number 1-3332.
- Plasmids pCI-Ssol, pCI-Ssol-CTE and pCI-Ssol-WPRE (deposited at the CNCM, on November 22, 2004, under number 1-3324) had previously been obtained by subcloning the excised KpnI-XhoI fragment. of the plasmid pcDNA-Ssol (see technical note of the DI 2004-106) between the NheI and XhoI sites of the plasmids pCI, pCI-S-CTE and pCI-S-WPRE respectively.)
- the plasmids pCI-Scube and pCI-Ssol encode for the same Ssol recombinant polypeptide.
- cell extracts were prepared in Laemmli-deposition buffer, separated on an 8% SDS-polyacrylamide gel and then transferred onto a PVDF membrane. (BioRad).
- the detection of this immunoblot (“western blot") was carried out using a rabbit anti-S rabbit polyclonal serum (PI 1135 rabbit immune serum: see Example 4 above) and polyclonal antibodies against donkey directed against rabbit IgG and coupled to peroxidase (NA934V, Amersham).
- the immunoblot is quantitatively revealed by luminescence using the ECL + kit (Amersham) and acquisition on a digital imaging device (FluorS, BioRad).
- Table XIV Use of a synthetic gene for the expression of S of SARS-CoV.
- Cell extracts prepared 48 hours after transfection of VerEE6 or 293T cells by plasmids pCI, pCI-S, pCI-S-CTE, pCI-S-WPRE and pCI-Ssynth were separated on an 8% SDS gel of acrylamide. and analyzed by western blot using a polyclonal anti-S rabbit antibody and a polyclonal anti-rabbit IgG (H + L) antibody coupled to peroxidase (NA934V, Amersham).
- the western blot is revealed by luminescence (ECL +, Amersham) and acquisition on a digital imaging device (FluorS, BioRad).
- the expression levels of the S protein were measured by quantifying the 2 majority bands identified in the image (see FIG. 33) and are indicated according to an arbitrary scale where the value of 1 represents the level measured at the time of transfection.
- pCI-S-WPRE plasmid The western blot is revealed by luminescence (ECL +, Amersham) and acquisition on a digital imaging device (FluorS, BioRad).
- the expression levels of the S protein were measured by quantifying the 2 majority bands identified in the image (see FIG. 33) and are indicated according to an arbitrary scale where the value of 1 represents the level measured at the time of transfection.
- the ability of the Scube synthetic gene to effectively direct synthesis and secretion of the Ssol polypeptide by mammalian cells was compared to that of the wild-type gene after transient transfection of hamster cells (BHK-21) and cells. human beings (293T).
- the plasmid pCI-Scube allows the expression of the Ssol polypeptide at 8-fold (BHK-21 cells) 20-fold (293T cells) higher levels than the plasmid pCI-Ssol .
- the levels of expression observed are of the order of 2-fold (293T cells) to 5-fold (BHK-21 cells) higher than those observed with the plasmid pCI-Ssol-WPRE.
- Table XV Use of a Synthetic Gene for the Expression of the Ssol Polypeptide
- the supernatants were harvested 48 hours after transfection of BHK or 293T cells by the plasmids pCI, pCI-Ssol, pCI-Ssol-CTE, pCI-Ssol-WPRE and pCI-Scube and quantitatively analyzed for the secretion of the Ssol polypeptide by an ELISA-specific capture of the Ssol polypeptide. Transfections were performed in duplicate and results are shown as mean and standard deviation of Ssol polypeptide concentrations (ng / ml) measured in the supernatants.
- VV vaccinia virus
- SARS-CoV SARS-associated coronavirus
- the inventors have been interested in the spike protein (S) of SARS-CoV, which makes it possible to induce after immunization of the animal in neutralizing antibodies the infectivity of SARS-CoV, as well as to a form soluble and secreted of this protein, the Ssol polypeptide, which is composed of the ectodomaine (aa 1-1193) of the S fused at its C-ter end to a FLAG tag (DYKDDDDK) via a BspEl linker encoding the dipeptide SG .
- S spike protein
- This Ssol polypeptide has an antigenicity similar to that of the protein S and allows, after injection into the mouse in the form of a purified protein supplemented with aluminum hydroxide, the induction of high titers of neutralizing antibodies against SARS. CoV.
- the different forms of the S gene were placed under the control of the 7.5K gene promoter and introduced into the thymidine kinase (TK) locus of the Copenhagen strain of vaccinia virus by double homologous recombination in vivo.
- TK thymidine kinase
- a synthetic late promoter was chosen in place of the 7.5K promoter, to increase the production of S and Ssol during late phases of the viral cycle.
- Plasmid pTG186poly is a transfer plasmid for the construction of recombinant vaccinia viruses (Kieny, 1986, Biotechnology, 4: 790-795). As such, it contains the VV thymidine kinase gene into which the 7.5K gene promoter has been inserted followed by a multiple cloning site allowing the insertion of heterologous genes (FIG. 34A).
- the 7.5K gene promoter actually contains a tandem of two active promoter sequences respectively during the early (P E ) and late (P L ) phases of the vaccinia virus replication cycle.
- the BamHI-XhoI fragments were excised from the plasmids pTRIP-S and pcDNA-Ssol respectively and inserted between the BamHI and SmaI sites of the plasmid pTG186poly to give the plasmids pTG-S and pTG-Ssol (FIG. 34A). Plasmids pTG-S and pTG-Ssol were deposited at the CNCM, on December 2, 2004, under the numbers 1-3338 and 1-3339, respectively.
- Plasmids pTN480, pTN-S and pTN-Ssol were obtained from the plasmids pTG186poly, pTG-S and pTG-Ssol respectively, substituting the Ndel-PstI fragment containing the 7.5K promoter with a DNA fragment containing the promoter.
- synthetic late 480 which was obtained by hybridization of oligonucleotides 5'-TATGAGCTTT ⁇ TTTTTTTGGC ATATAAATAG ACTCGGCGCG CCATCTGCA-3 'and 5'-GATGGCGCGC CGAGTCTATT TATATGCCAA AAAAAAAAAA AAAAAAAAGC TCA-3' (Fig. 34B).
- the insert was sequenced using a BigDye Terminator vl.l kit (Applied Biosystems) and an ABI377 automatic sequencer.
- the late synthetic promoter 480 sequence as cloned into the pTN series transfer plasmids is shown in Figure 34C. Plasmids pTN-S and pTN-Ssol were deposited at the CNCM on December 2, 2004, under the numbers 1-3340 and 1-3341, respectively. Recombinant vaccinia viruses were obtained by double in vivo homologous recombination between the TK cassette of the pTG and pTN series transfer plasmids and the TK gene of the Copenhagen strain of vaccinia virus according to a procedure described by Kieny et al.
- CV-1 cells are transfected using DOTAP (Roche) with genomic DNA of the Copenhagen strain of vaccinia virus and each of the pTG and pTN series transfer plasmids described above, then superinfected with vaccinia virus VV-ts7 for 24 hours at 33 ° C.
- the helper virus is counter-selected by incubation at 40 ° C. for 2 days and then the recombinant viruses (TK- phenotype) selected by two cycles of cloning under 143Btk- agar medium in the presence of BuDr (25 ⁇ g / ml).
- the 6 viruses VV-TG, VV-TG-S, VV-TG-Ssol, VV-TN, VV-TN-S and VV-TN-Ssol were respectively obtained using the transfer plasmids pTG186poly, pTG- S, pTG-Ssol, pTN480, pTN-S, pTN-Ssol.
- the VV-TG and VV-TN viruses do not express any heterologous genes and were used as a TK-control in the experiments.
- Recombinant virus preparations were performed on monolayers of CV-1 or BHK-21 cells and the plaque-forming unit titer (ufp) determined on CV-1 cells according to Earl and Moss (1998, Current Protocols in Molecular Biology, 16.16. 1-16.16.13).
- ufp plaque-forming unit titer
- VV-TN-S directs the expression of the S protein at levels which are comparable to those which can be observed 8h after infection with SARS-CoV but which are well higher than those that can be observed after infection with VV-TG-S.
- FIG. 35A the recombinant virus VV-TN-S directs the expression of the S protein at levels which are comparable to those which can be observed 8h after infection with SARS-CoV but which are well higher than those that can be observed after infection with VV-TG-S.
- VV-TN-S and VV-TN-Ssol the levels of expression observed after infection by the TN series viruses (VV-TN-S and VV-TN-Ssol) are approximately 10-fold higher than those observed with the TG series viruses (VV-TG-S and VV-TG-Ssol respectively).
- the Ssol polypeptide is secreted into the VV-TN-Ssol virus-infected CV-1 cell supernatant more efficiently than in the VV-TG-Ssol infected cell supernatant (Fig. 36A).
- the VV-TN-Sflag virus was used as a control because it expresses the membrane form of the S protein fused at its C-ter end to the FLAG tag.
- the Sflag protein is not detected in the supernatant of VV-TN-Sflag infected cells, demonstrating that the Ssol polypeptide is well secreted actively after infection with VV-TN-Ssol.
- S membrane form
- Ssol soluble and secreted form
- the vaccinia viruses carrying the synthetic promoter 480 allow the expression of S and the secretion of Ssol at much higher levels than the viruses carrying the promoter of the 7.5K gene.
- the BHK-21 line is the cell line that secretes the highest amounts of Ssol polypeptide after infection with the VV-TN-Ssol virus among the tested lines (BHK-21, CV1, 293T and FrhK-4, FIG. 36B); it allows the production and the purification in quantity of the recombinant polypeptide Ssol.
- the BHK-21 cells are seeded in a standard culture medium (DMEM without pyruvate containing 4.5 g / l of glucose and supplemented with 5% of TPB, 5%> S VF, 100 U / ml penicillin and 100 ⁇ g / ml streptomycin) as a subconfluent monolayer (10 million cells for each 100 cm 2 in 25 ml of medium).
- DMEM without pyruvate containing 4.5 g / l of glucose and supplemented with 5% of TPB, 5%> S VF, 100 U / ml penicillin and 100 ⁇ g / ml streptomycin
- the culture supernatant is removed after 2.5 days of incubation at 35 ° C. and 5% of CO 2 and inactivated vaccinia virus by addition of triton X-100 (0.1%).
- PES polyethersulphone
- the recombinant Ssol polypeptide is purified by anti-FLAG matrix affinity chromatography with elution with a solution of FLAG peptide (DYKDDDDK) at 100 ⁇ g / ml in TBS (Tris 50mM pH 7.4, 150 mMNaCl).
- the purification scheme presented makes it possible to purify on the order of 160 ⁇ g of Ssol polypeptide per liter of culture supernatant.
- the ELISA reactivity of the recombinant Ssol polypeptide was analyzed against sera from SARS patients. The sera of probable cases of SARS tested were chosen on the basis of the results (positive or negative) of analysis of their specific reactivity with respect to the native SARS-CoV antigens by immunofluorescence test on SARS-infected VeroE6 cells. -CoV and / or by indirect ELISA using as antigen a lysate of VeroE6 cells infected with SARS-CoV.
- the sera of these patients are identified by a serial number of the National Influenza Reference Center as well as the initials of the patient and the number of days since the onset of symptoms. All sera from probable cases (see Table XVI) recognize the native SARS-CoV antigens with the exception of the 032552 serum of the ATV patient, for whom infection with SARS-CoV could not be confirmed by RT-PCR performed on respiratory samples on days 3, 8 and 12. A panel of control sera was used as a control (TV serums): these are sera taken in France before the SARS epidemic in 2003. .
- Solid phases sensitized by the recombinant polypeptide Ssol were prepared by adsorption of a solution of purified Ssol polypeptide at 4 ⁇ g / ml in PBS in the wells of an ELISA plate.
- the plates are incubated overnight at 4 ° C and then washed with PBS-Tween buffer (PBS, 0.1% Tween20). After washing in PBS-tween, the sera to be tested (100 .mu.l) are diluted 1/100 and 1/400 in PBS-skimmed-Tween buffer (PBS, 3%> skimmed milk, 0.1% Tween). then added to the wells of the sensitized ELISA plate. The plates are incubated for 1 h at 37 ° C.
- mice groups of 7 BALB / c mice were immunized iv twice at 4-week intervals with 10 6 pfu of recombinant vaccinia virus VV-TG, VV-TG-S, VV-TG-Ssol, VV-TN, VV-TN-S and VV-TN-Ssol as well as, as a control, VV-TG-HA which directs the expression of the hemagglutinin strain A / PR 8/34 of the influenza.
- the immune sera were taken 3 weeks after each of the immunizations (IS1, IS2).
- Immune sera were pooled for each of the groups by indirect ELISA using a VeroE6 cell lysate infected with SARS-CoV as the antigen and as a control, a lysate of uninfected VeroE6 cells.
- the anti-SARS-CoV antibody titers (TI) are calculated as the reciprocal of the dilution producing a specific OD of 0.5 after revelation with a mouse anti-mouse IgG (H + L) polyclonal antibody coupled with peroxidase ( NA931V, Amersham) and TMB supplemented with H 2 O 2 (KPL). This analysis (FIG.
- Immune sera were pooled for each group for their ability to seroneutralize the infectivity of SARS-CoV. 4 seroneutralization points on FRhK-4 cells (100 TCID50 of SARS-CoV) are produced for each reason dilutions 2 tested from 1/20.
- the seroneutralizing titer is calculated according to the method of Reed and Munsch as the inverse of the dilution neutralizing the infectivity of 2 out of 4 cups.
- recombinant viras vaccinas are capable of expressing larger amounts of the S and Ssol antigens and thus of having increased immunogenicity.
- the recombinant VV-TN-Ssol vaccinia virus can be used for the production and purification of the Ssol antigen for diagnostic (ELISA serology) and vaccine (subunit vaccine) applications.
- Example 17 Recombinant measles virus expressing SARS-associated coronavirus spike protein (S) (SARS-CoV). Vaccine applications.
- SARS-associated coronavirus spike protein S
- Vaccine applications 1) Introduction Measles vaccine (MV) induces in humans a long-lasting protective immunity after a single injection (Hilleman, 2002, Vaccine, 20: 651-665). The protection conferred is very robust and relies on the induction of an antibody response and a CD4 and CD8 cell response. The MV genome is very stable and no reversion to the virulence of the vaccine strains has ever been observed.
- MV Measles vaccine
- the measles virus belongs to the genus Morbillivirus family Paramyxoviridae; it is an enveloped viras whose genome is a single-stranded RNA of negative polarity of 16kb (FIG. 40A) and whose exclusively cytoplasmic replication cycle excludes any possibility of integration into the genome of the host.
- the measles vaccine is one of the most effective and safest live vaccines used in the human population.
- Frederic Tangy's team recently developed an expression vector based on the Schwarz strain of measles virus, which is the safest and most widely used attenuated strain in humans as a measles vaccine.
- This vaccine strain can be isolated from an infectious molecular clone by maintaining its immunogenicity in primates as well as in susceptible mice. It constitutes, after insertion of additional transcription units, a vector for the expression of heterologous sequences (Combredet, 2003, J. Virol 77: 11546-11554).
- a recombinant MV Schwarz expressing the West Nile Virus (WNV) envelope glycoprotein induces an effective and long-lasting antibody response that protects the mouse from lethal challenge infection by WNV (Despres et al, 2004, J. Infect, Dis., In press). All these characteristics make the Schwarz attenuated strain of measles viras an extremely promising vector candidate for the construction of new live recombinant vaccines.
- the purpose of this example is to evaluate the ability of recombinant viral measles (MV) expressing different SARS-associated coronavirus (SARS-CoV) antigens to form new SARS vaccine candidates.
- MV viral measles
- SARS-CoV SARS-associated coronavirus
- SARS-CoV which makes it possible to induce, after animal immunization, antibodies neutralizing the infectivity of SARS-CoV, as well as to a soluble and secreted form of this protein
- the Ssol polypeptide which is composed of ectodomain (aa 1-1193) of the S fused at its C-ter end to a FLAG tag (DYKDDDDK) via a BspE1 linker encoding the SG dipeptide.
- This Ssol polypeptide has an antigenicity similar to that of the protein S and allows, after injection into the mouse in the form of a purified protein supplemented with aluminum hydroxide, the induction of high titers of neutralizing antibodies against SARS. CoV.
- the different forms of the S gene have been introduced as an additional transcription unit between the P (phosphoprotein) and M (template) genes in the cDNA of the previously described MV Schwarz strain (Combredet, 2003, J. Virol 77: 11546-11554; EP Application No. 02291551.6 of the 20 June 2002, and EP Application No. 02291550.8 of June 20, 2002).
- MVSchw2-SARS-S and MVSchw2-SARS-Ssol recombinant viras After isolating MVSchw2-SARS-S and MVSchw2-SARS-Ssol recombinant viras and verifying their ability to express S antigen from SARS-CoV, their ability to induce a protective immune response against SARS in mice and monkeys is tested.
- 2) Construction of the Recombinant Viruses The plasmid pTM-MVSchw-ATU2 (FIG.
- MV 40B contains an infectious cDNA corresponding to the antigenome of the Schwarz measles virus (MV) vaccine strain in which an additional transcription unit (ATU) has was introduced between the P (phosphoprotein) and M (matrix) genes (Combredet, 2003, Journal of Virology, 77: 11546-11554).
- ATU additional transcription unit
- Recombinant MVSchw2-SARS-S and MVSchw2-SARS-Ssol genomes of the measles virus were constructed by inserting the ORFs of the S protein and the Ssol polypeptide into the additional transcription unit of the MVSchw-ATU2 vector.
- a DNA fragment containing the SARS-CoV S cDNA was amplified by PCR using the oligonucleotides 5'-ATACGTACGA CCATGTTTAT TTTCTTATTA TTTCTTACTC TCACT-3 'and 5'-ATAGCGCGCT CATTATGTGT AATGTAATTT GACACCCTTG-3 using the pcDNA-S plasmid as a template and then inserted into the plasmid pCR®2.1-TOPO (Invitrogen) to obtain the plasmid pTOPO-S-MV.
- the two oligonucleotides used contain BsiW1 and BssHII restriction sites, so as to allow subsequent insertion into the measles vector, and were designed to generate a sequence of 3774 nt including the initiation and termination codons, in order to to respect the rule of 6 which states that the genome length of a measles virus must be divisible by 6 (Calain & Roux, 1993, J. Virol, 67: 4822-4830, Schneider et al., 1997, Virology, 227 : 314-322).
- the insert was sequenced using a BigDye Terminator vl.l kit (Applied Biosystems) and an ABI377 automatic sequencer.
- a plasmid containing the Ssol polypeptide cDNA corresponding to ectodomaine (aa 1-1193) of S-SARS-CoV fused at its C-terminus In order to express a soluble and secreted form of SARS-CoV S, a plasmid containing the Ssol polypeptide cDNA corresponding to ectodomaine (aa 1-1193) of S-SARS-CoV fused at its C-terminus. The sequence of a FLAG tag (DYKDDDDK) via a BspE1 linker encoding the dipeptide SG was then obtained.
- a DNA fragment was amplified using the oligonucleotides 5'-CCATTTCAAC AATTTGGCCG-3 'and 5'- ATAGGATCCG CGCGCTCATT ATTTATCGTC GTCATCTTTA TAATC-3 'from the plasmid pCDNA-Ssol and then inserted into the plasmid pTOPO-S-MV between the SalI and BamHI sites to obtain the plasmid pTOPO-S-MV-SF.
- the generated sequence is 3618 nt long between the BsiW1 and BssHII sites and follows the rule of 6.
- the insert was sequenced as above.
- the BsiW1 -BssHII fragments containing the cDNAs of the S protein and of the Ssol polypeptide were then excised by digesting the pTOPO-S-MV and pTOPO-S-MV-SF plasmids and then subcloned between the corresponding sites of the pTM-MVSchw plasmid.
- -ATU2 to give plasmids pTM-MVSchw2-SARS-S and pTM-MVSchw2-SARS-Ssol ( Figure 40B). These two plasmids were deposited at the CNCM on December 1, 2004, under numbers 1-3326 and 1-3327, respectively.
- the recombinant measles viruses corresponding to plasmids pTM-MVSchw2-SARS-S and pTM-MVSchw2-SARS-Ssol were obtained by reverse genetics according to the system based on the use of an auxiliary cell line, described by Radecke et al. (1995, Embo J., 14: 5773-5784) and modified by Parl s et al. (1999, J. Virol, 73: 3560-3566).
- the 293-3-46 helper cells are transfected according to the calcium phosphate method with 5 ⁇ g of the plasmids pTM-MVSchw2-SARS-S or pTM-MVSchw2-SARS-Ssol and 0.02 ⁇ g of the plasmid pEMC. expression of MV L polymerase (gift from MA Billeter). After overnight incubation at 37 ° C, heat shock was performed for 2 hours at 43 ° C and the transfected cells were transferred to a monolayer of Vero cells.
- syncytia appeared after 2 to 3 days of co-culture and were transferred successively to monolayers of Vero cells at 70% confluence in 35 mm petri dishes and then in bottles of 25 and 75 ml. cm 2 .
- syncytia reaches 80-90% confluence, cells are scraped off and frozen and thawed once. After low speed centrifugation, the virus-containing supernatant is stored in an aliquot at -80 ° C.
- the MVSchw2-SARS-S and MVSchw2-SARS-Ssol recombinant virus titers were determined by limiting dilution on Vero cells and the infective dose titre 50% o cups (TCID 5 o) calculated according to the Kârber method. 3) Characterization of the recombinant viruses The expression of the transgenes encoding the S protein and the Ssol polypeptide was searched by Western blot and immunofluorescence. Vero cell monolayers in T-25 flasks were infected at a multiplicity of 0.05 by different runs of both MVSchw2-SARS-S and MVSchw2-SARS-Ssol viras and wild-type MWSchw viras as controls.
- cytoplasmic extracts were prepared in extraction buffer (150mM NaCl, 50mM Tris-HCl pH 7.2, 1% triton-X-100, 0.1 % SDS, 1% DOC) and then diluted in Laemmli deposition buffer, separated on an 8% SDS gel of polyacrylamide and transferred onto a PVDF membrane (BioRad).
- the detection of this immunoblot (“western blot") was carried out using a rabbit anti-S rabbit polyclonal serum (PI 1135 rabbit immune serum: see Example 4 above) and polyclonal antibodies against donkey directed against rabbit IgG and coupled to peroxidase (NA934V, Amersham).
- the fixed antibodies were revealed by luminescence using the ECL + kit (Amersham) and Hyperfilm MP autoradiography films (Amersham). Vero cells in monolayers on glass slides were infected with both MVSchw2-SARS-S and MVSchw2-SARS-Ssol and wild-type MWSchw for control at infection multiplicities of 0.05.
- the cells were fixed in a solution of PBS-PFA 4%>, permeabilized with a solution of PBS containing 0.2% triton and then labeled with polyclonal antibodies of rabbits hyperimmunized by purified and inactivated virions of SARS-CoV and a conjugate of goat anti-IgG (H + L) antibody. rabbit coupled with FITC (Jackson). As shown in FIGS.
- the MVSchw2-SARS-S and MVSchw2-SARS-Ssol recombinant viruses direct the expression of the S protein and the Ssol polypeptide respectively at levels comparable to those that can be observed 8 hours later.
- SARS-CoV infection The expression of these polypeptides is stable after 3 passages of the recombinant viras in cell culture.
- the Ssol polypeptide is expected to be secreted from MVSchw2-SARS-Ssol viras infected cells as is the case when this same polypeptide is expressed in mammalian cells after transient transfection of the cognate sequences (see Example 11). above).
- MVSchw2-SARS-S and MVSchw2-SARS-Ssol viruses allow the expression of S of SARS-CoV, their ability to induce a protective immune response against SARS-CoV in CD46 + mice. IFN- ⁇ R "A , which is susceptible to infection with MV, is evaluated.
- the antibody response of the immunized mice is evaluated by ELISA against the native SARS-CoV antigens and for their ability to neutralize the infectivity of SARS-CoV in vitro, using the methodologies described above.
- the protective power of the response will be assessed by measuring the reduction in pulmonary viral load 2 days after non-lethal challenge infection with SARS-CoV.
- Second-generation recombinant measles viruses are constructed by substituting wild-type S and Sol genes for synthetic genes optimized for mammalian cell expression, as described in Example 15 above. These recombinant measles viruses are capable of expressing larger amounts of S and Ssol antigens and thus of having increased immunogenicity.
- the wild-type or synthetic genes coding for the S protein or the Ssol polypeptide can be inserted into the MVSchw-ATU3 measles vector in the form of an additional transcription unit located between the H and L genes, then the recombinant viras produced and characterized in a similar manner.
- This insertion is likely to generate recombinant viruses with different characteristics (multiplication of the virus, level of expression of the transgene) and possibly an improved immunogenicity compared to those obtained after insertion of the transgenes between the P and N genes.
- the recombinant measles virus MVSchw2-SARS-Ssol can be used for the quantitative production and purification of the Ssol antigen for diagnostic and vaccine applications.
- Example 18 Other Applications Related to Protein S a) Lentiviral vectors allowing the expression of S or Ssol (or even fragments of S) can constitute a recombinant vaccine against SARS-CoV, for use in human prophylaxis and veterinary. In order to demonstrate the feasibility of such a vaccine, the immunogenicity of recombinant lentiviral vectors TRIP-SD / SA-S-WPRE and TRIP-SD / SA-Ssol-WPRE is studied in mice. b) Monoclonal antibodies are produced using the recombinant polypeptide Ssol.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006541979A JP5090741B2 (ja) | 2003-12-02 | 2004-12-02 | 新規なsars関連コロナウイルス系統のゲノムによりコードされるタンパク質及びペプチドの利用 |
CA002549188A CA2549188A1 (fr) | 2003-12-02 | 2004-12-02 | Utilisation des proteines et des peptides codes par le genome d'une nouvelle souche de coronavirus associe au sras |
US10/581,354 US20070275002A1 (en) | 2003-12-02 | 2004-12-02 | Use Of Proteins And Peptides Encoded By The Genome Of A Novel Sars-Associated Coronavirus Strain |
EP04805624A EP1697507B1 (fr) | 2003-12-02 | 2004-12-02 | Utilisation des proteines et des peptides codes par le genome d'une nouvelle souche de coronavirus associe au sras |
PL04805624T PL1697507T3 (pl) | 2003-12-02 | 2004-12-02 | Zastosowanie białek i peptydów kodowanych przez genom nowego szczepu koronawirusa związanego z SARS |
US13/187,011 US20120082693A1 (en) | 2003-12-02 | 2011-07-20 | Use of proteins and peptides encoded by the genome of a novel sars-associated coronavirus strain |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0314152A FR2862981B1 (fr) | 2003-12-02 | 2003-12-02 | Nouvelle souche de coronavirus associe au sras et ses applications |
FR0314151A FR2862974B1 (fr) | 2003-12-02 | 2003-12-02 | Utilisation des proteines et des peptides codes par le genome d'une nouvelle souche de coronavirus associe au sras |
FR0314151 | 2003-12-02 | ||
FR0314152 | 2003-12-02 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/187,011 Continuation US20120082693A1 (en) | 2003-12-02 | 2011-07-20 | Use of proteins and peptides encoded by the genome of a novel sars-associated coronavirus strain |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005056781A1 true WO2005056781A1 (fr) | 2005-06-23 |
Family
ID=34680402
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2004/003106 WO2005056584A2 (fr) | 2003-12-02 | 2004-12-02 | Nouvelle souche de coronavirus associe au sras et ses applications. |
PCT/FR2004/003105 WO2005056781A1 (fr) | 2003-12-02 | 2004-12-02 | Utilisation des proteines et des peptides codes par le genome d'une nouvelle souche de coronavirus associe au sras. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2004/003106 WO2005056584A2 (fr) | 2003-12-02 | 2004-12-02 | Nouvelle souche de coronavirus associe au sras et ses applications. |
Country Status (9)
Country | Link |
---|---|
US (4) | US20070275002A1 (fr) |
EP (4) | EP2275534A1 (fr) |
JP (3) | JP5090741B2 (fr) |
AT (1) | ATE476498T1 (fr) |
CA (2) | CA2549188A1 (fr) |
DE (1) | DE602004028506D1 (fr) |
ES (1) | ES2396127T3 (fr) |
PL (1) | PL1697507T3 (fr) |
WO (2) | WO2005056584A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010063685A1 (fr) * | 2008-12-02 | 2010-06-10 | Glaxosmithkline Biologicals S.A. | Vaccin |
WO2021188837A1 (fr) * | 2020-03-20 | 2021-09-23 | The Johns Hopkins University | Prophylaxie et traitement d'infections à coronavirus pathogène |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2432738A1 (fr) * | 2003-02-26 | 2004-08-26 | Philippe Despres | Nouvelles proteines des virus de la dengue et du nil et genes codant pour ces proteines, et leurs utilisations dans des vaccins et dans des applications therapeutiques et diagnostiques |
ES2347812T3 (es) * | 2006-07-25 | 2010-11-04 | Institut Pasteur | Cepa de mycobacterium recombinante que expresa una proteina fap micobacteriana bajo el control de un promotor activo en hipoxia y su aplicacion para terapia de cancer. |
EP1939214B1 (fr) | 2006-12-22 | 2013-07-10 | Institut Pasteur | Cellules et méthodes pour générer des virus à ARN, non-segmenté et de brin négatif |
GB0711858D0 (en) * | 2007-06-19 | 2007-07-25 | Glaxosmithkline Biolog Sa | Vaccine |
EP3907297A1 (fr) | 2011-04-15 | 2021-11-10 | The Johns Hopkins University | Système de séquençage sûr |
CA2889937C (fr) | 2012-10-29 | 2020-12-29 | The Johns Hopkins University | Test de papanicolaou pour les cancers de l'ovaire et de l'endometre |
GB201318804D0 (en) * | 2013-10-24 | 2013-12-11 | Adaptimmune Ltd | Vectors for transgene expression |
SG10201913406SA (en) * | 2014-07-18 | 2020-03-30 | Celltheon Corp | Methods and compositions for expression of polypeptides in a cell |
US10072309B1 (en) * | 2015-05-08 | 2018-09-11 | Dougbeh-Chris Nyan | Methods for real-time multiplex isothermal detection and identification of bacterial, viral, and protozoan nucleic acids |
US11286531B2 (en) | 2015-08-11 | 2022-03-29 | The Johns Hopkins University | Assaying ovarian cyst fluid |
KR20200115450A (ko) | 2017-08-07 | 2020-10-07 | 더 존스 홉킨스 유니버시티 | 암을 평가하고 치료하기 위한 방법 및 재료 |
WO2021160346A1 (fr) * | 2020-02-13 | 2021-08-19 | Institut Pasteur | Vaccin à base d'acide nucléique contre le coronavirus sars-cov-2 |
CA3167496A1 (fr) * | 2020-02-14 | 2021-08-19 | Anne De Groot | Epitopes de lymphocytes t regulateurs et antigenes sars-cov-2 detoleres |
GB2594683A (en) * | 2020-02-17 | 2021-11-10 | Vaxbio Ltd | Vaccine |
CN111334608B (zh) * | 2020-02-19 | 2022-04-12 | 北京亿森宝生物科技有限公司 | 用于检测新型冠状病毒2019-nCoV的双重荧光冻干微芯片、试剂盒及方法 |
WO2021170035A1 (fr) * | 2020-02-25 | 2021-09-02 | 广州复能基因有限公司 | Étalon de référence de test d'acide nucléique de virus d'arn et son utilisation |
WO2021188906A1 (fr) * | 2020-03-19 | 2021-09-23 | Nature's Toolbox, Inc. | Nouveau vaccin multivalent covid-19 à base d'arnm et ses procédés de production mis à l'échelle |
WO2021188966A1 (fr) * | 2020-03-19 | 2021-09-23 | Massachusetts Institute Of Technology | Peptides se liant aux protéines de spicule du sras-cov-2 |
WO2021189032A1 (fr) * | 2020-03-20 | 2021-09-23 | Yu Ruey J | Coronavirus : détection et traitement précoces |
WO2021188991A1 (fr) * | 2020-03-20 | 2021-09-23 | BioVaxys Inc. | Protéines spike hapténisée de coronavirus |
US20230122364A1 (en) * | 2020-03-27 | 2023-04-20 | Vanderbilt University | HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) |
IT202000006754A1 (it) | 2020-03-31 | 2021-10-01 | Diasorin S P A | Saggi per la rivelazione di SARS-CoV-2 |
US11149320B1 (en) | 2020-03-31 | 2021-10-19 | Diasorin S.P.A. | Assays for the detection of SARS-CoV-2 |
US20210311054A1 (en) | 2020-04-01 | 2021-10-07 | Institut Pasteur | Severe acute respiratory syndrome (sars) - associated coronavirus diagnostics |
US10948490B1 (en) * | 2020-04-01 | 2021-03-16 | Institut Pasteur | Severe acute respiratory syndrome (SARS)—associated coronavirus diagnostics |
US11815513B2 (en) | 2020-04-01 | 2023-11-14 | Institut Pasteur | Severe acute respiratory syndrome (SARS)-associated coronavirus diagnostics |
WO2021205083A2 (fr) | 2020-04-11 | 2021-10-14 | Finindsutria Srl | Composition pour la prévention ou le traitement du covid-19 |
GB202307565D0 (en) | 2020-04-22 | 2023-07-05 | BioNTech SE | Coronavirus vaccine |
WO2021220137A2 (fr) * | 2020-04-27 | 2021-11-04 | Sapir Pharmaceuticals Inc. | Inhibiteurs de pannexine-1 pour le traitement de la covid-19 de patients infectés par le sras-cov-2 avec ou sans syndrome respiratoire aigu associé |
WO2021236869A2 (fr) * | 2020-05-20 | 2021-11-25 | The Johns Hopkins University | Procédés de détection de virus |
CN116348101A (zh) * | 2020-06-05 | 2023-06-27 | 瓦克萨特公司 | 嵌合腺病毒载体 |
CN111830120B (zh) * | 2020-06-10 | 2023-06-09 | 北京东西分析仪器有限公司 | 应用质谱***鉴定新冠病毒的试剂盒及其使用方法 |
WO2021252901A2 (fr) * | 2020-06-12 | 2021-12-16 | The Penn State Research Foundation | Cocktail de préparation à une pandémie pour lutter contre les épidémies de coronavirus |
WO2022150740A1 (fr) * | 2021-01-11 | 2022-07-14 | Board Of Regents, The University Of Texas System | Anticorps à réaction croisée reconnaissant le domaine s2 de spicule de coronavirus |
WO2023287324A1 (fr) * | 2021-07-16 | 2023-01-19 | Joint Stock Company "Biocad" | Virus recombiné isolé basé sur le virus de la grippe |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
SI1695985T1 (sl) | 1997-04-07 | 2011-06-30 | Genentech Inc | Postopki za tvorbo humaniziranih protiteles z naključno mutagenezo |
US20020064801A1 (en) * | 1999-12-01 | 2002-05-30 | Ryan Jeffrey R. | Novel and practical serological assay for the clinical diagnosis of leishmaniasis |
BR0209837A (pt) * | 2001-05-17 | 2004-12-14 | Univ Utrecht | Partìcula semelhante a vìrus isolada ou recombimante capaz de replicação, composição, e, método para inibir ou bloquear uma infecção com um coronavìrus ou partìcula semelhante a coronavìrus |
US7220852B1 (en) * | 2003-04-25 | 2007-05-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Coronavirus isolated from humans |
US8080642B2 (en) * | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
US20050100883A1 (en) * | 2003-11-12 | 2005-05-12 | Wang Chang Y. | Peptide-based diagnostic reagents for SARS |
EP3330413B1 (fr) | 2008-06-04 | 2020-09-09 | SixPoint Materials, Inc. | Procédé de croissance de cristaux de nitrure du groupe iii faisant appel à un récipient haute pression |
BRPI0823394A2 (pt) | 2008-12-23 | 2015-06-16 | Calera Corp | Sistema e método eletroquímico de hidróxido de baixa energia |
-
2004
- 2004-12-02 CA CA002549188A patent/CA2549188A1/fr not_active Abandoned
- 2004-12-02 WO PCT/FR2004/003106 patent/WO2005056584A2/fr active Application Filing
- 2004-12-02 AT AT04805625T patent/ATE476498T1/de not_active IP Right Cessation
- 2004-12-02 CA CA002549594A patent/CA2549594A1/fr not_active Abandoned
- 2004-12-02 ES ES04805624T patent/ES2396127T3/es active Active
- 2004-12-02 US US10/581,354 patent/US20070275002A1/en not_active Abandoned
- 2004-12-02 PL PL04805624T patent/PL1697507T3/pl unknown
- 2004-12-02 EP EP10005885A patent/EP2275534A1/fr not_active Withdrawn
- 2004-12-02 US US10/581,356 patent/US7736850B2/en active Active
- 2004-12-02 EP EP10012268A patent/EP2361974A1/fr not_active Withdrawn
- 2004-12-02 EP EP04805624A patent/EP1697507B1/fr active Active
- 2004-12-02 JP JP2006541979A patent/JP5090741B2/ja not_active Expired - Fee Related
- 2004-12-02 JP JP2006541980A patent/JP5054384B2/ja not_active Expired - Fee Related
- 2004-12-02 DE DE602004028506T patent/DE602004028506D1/de active Active
- 2004-12-02 WO PCT/FR2004/003105 patent/WO2005056781A1/fr active Application Filing
- 2004-12-02 EP EP04805625A patent/EP1694829B1/fr active Active
-
2010
- 2010-04-06 US US12/754,908 patent/US8343718B2/en active Active
-
2011
- 2011-07-20 US US13/187,011 patent/US20120082693A1/en not_active Abandoned
-
2012
- 2012-04-12 JP JP2012091153A patent/JP2012165750A/ja not_active Withdrawn
Non-Patent Citations (3)
Title |
---|
DATABASE UNIPROT 10 October 2003 (2003-10-10), XP002294755, Database accession no. P59594 * |
MARRA M A ET AL: "The genome sequence of the SARS-associated coronavirus", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 300, no. 5624, 30 May 2003 (2003-05-30), pages 1399 - 1404, XP002269483, ISSN: 0036-8075 * |
WANG J ET AL: "ASSESSMENT OF IMMUNOREACTIVE SYNTHETIC PEPTIDES FROM THE STRUCTURAL PROTEINS OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS", CLINICAL CHEMISTRY, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY. WINSTON, US, vol. 49, no. 12, 13 November 2003 (2003-11-13), pages 1989 - 1996, XP001182489, ISSN: 0009-9147 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010063685A1 (fr) * | 2008-12-02 | 2010-06-10 | Glaxosmithkline Biologicals S.A. | Vaccin |
WO2021188837A1 (fr) * | 2020-03-20 | 2021-09-23 | The Johns Hopkins University | Prophylaxie et traitement d'infections à coronavirus pathogène |
Also Published As
Publication number | Publication date |
---|---|
US8343718B2 (en) | 2013-01-01 |
EP1694829B1 (fr) | 2010-08-04 |
ATE476498T1 (de) | 2010-08-15 |
JP2007536907A (ja) | 2007-12-20 |
CA2549188A1 (fr) | 2005-06-23 |
JP2007512826A (ja) | 2007-05-24 |
US20070128224A1 (en) | 2007-06-07 |
US20070275002A1 (en) | 2007-11-29 |
EP2275534A1 (fr) | 2011-01-19 |
EP1697507B1 (fr) | 2012-09-19 |
US20120082693A1 (en) | 2012-04-05 |
WO2005056584A3 (fr) | 2005-08-25 |
EP1697507A1 (fr) | 2006-09-06 |
US7736850B2 (en) | 2010-06-15 |
US20110065089A1 (en) | 2011-03-17 |
WO2005056584A2 (fr) | 2005-06-23 |
PL1697507T3 (pl) | 2013-03-29 |
JP5090741B2 (ja) | 2012-12-05 |
JP2012165750A (ja) | 2012-09-06 |
CA2549594A1 (fr) | 2005-06-23 |
JP5054384B2 (ja) | 2012-10-24 |
ES2396127T3 (es) | 2013-02-19 |
EP2361974A1 (fr) | 2011-08-31 |
EP1694829A2 (fr) | 2006-08-30 |
DE602004028506D1 (de) | 2010-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1697507B1 (fr) | Utilisation des proteines et des peptides codes par le genome d'une nouvelle souche de coronavirus associe au sras | |
Godet et al. | Major receptor-binding and neutralization determinants are located within the same domain of the transmissible gastroenteritis virus (coronavirus) spike protein | |
Oleksiewicz et al. | Epitope mapping porcine reproductive and respiratory syndrome virus by phage display: the nsp2 fragment of the replicase polyprotein contains a cluster of B-cell epitopes | |
Mebatsion et al. | Newcastle disease virus (NDV) marker vaccine: an immunodominant epitope on the nucleoprotein gene of NDV can be deleted or replaced by a foreign epitope | |
Laurent et al. | Recombinant rabbit hemorrhagic disease virus capsid protein expressed in baculovirus self-assembles into viruslike particles and induces protection | |
US20040071709A1 (en) | Corona-virus-like particles comprising functionally deleted genomes | |
Jung et al. | The human ACE-2 receptor binding domain of SARS-CoV-2 express on the viral surface of the Newcastle disease virus as a non-replicating viral vector vaccine candidate | |
Laviada et al. | The use of African horse sickness virus NS3 protein, expressed in bacteria, as a marker to differentiate infected from vaccinated horses | |
Feng et al. | Towards our understanding of SARS-CoV, an emerging and devastating but quickly conquered virus | |
TR201808440T4 (tr) | Hendra ve nipah virüsü G glikoproteininin çözünebilen formları. | |
Bos et al. | The function of the spike protein of mouse hepatitis virus strain A59 can be studied on virus-like particles: cleavage is not required for infectivity | |
Duckmanton et al. | Bovine torovirus: sequencing of the structural genes and expression of the nucleocapsid protein of Breda virus | |
FR2862981A1 (fr) | Nouvelle souche de coronavirus associe au sras et ses applications | |
FR2732346A1 (fr) | Proteines mutees, codees par un gene env mute de lentivirus, fragments peptidiques inclus dans lesdites proteines, vecteurs d'expression exprimant lesdites proteines mutees et leurs applications | |
WO2014030137A1 (fr) | Souche vaccinale marquée du virus de la peste des petits ruminants, et son procédé d'obtention. | |
FR2866025A1 (fr) | Utilisation des proteines et des peptides codes par le genome d'une nouvelle souche de coronavirus associe au sras | |
Pulford et al. | Intracellular processing of the porcine coronavirus transmissible gastroenteritis virus spike protein expressed by recombinant vaccinia virus | |
FR2862974A1 (fr) | Utilisation des proteines et des peptides codes par le genome d'une nouvelle souche de coronavirus associe au sras | |
Luo et al. | Analysis of Antigenic Cross‐Reactivity Between Subgroup C Avian Pneumovirus and Human Metapneumovirus by Using Recombinant Fusion Proteins | |
Subbarao | SARS vaccines | |
Makino et al. | Severe Acute Respiratory Syndrome | |
Arndt | Role of the coronavirus membrane protein in virus assembly | |
Chen | Identification and Characterization of Neutralizing Epitopes on Spike Protein of Turkey Coronavirus | |
Lu | Interaction of SARS-CoV spike protein with lipid rafts of host cells during viral entry | |
Petit | Genetics and functions of the SARS coronavirus spike protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2549188 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006541979 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3282/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004805624 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200480041255.7 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004805624 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10581354 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10581354 Country of ref document: US |